



University of Dundee

Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals

LifeLines Cohort Study; EPIC-CVD Consortium; EPIC-InterAct Consortium; Understanding Society Scientific Group; Million Veteran Program; Surendran, Praveen

Published in:
Nature Genetics

DOI:
[10.1038/s41588-020-00713-x](https://doi.org/10.1038/s41588-020-00713-x)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

LifeLines Cohort Study, EPIC-CVD Consortium, EPIC-InterAct Consortium, Understanding Society Scientific Group, Million Veteran Program, Surendran, P., Feofanova, E. V., Lahrouchi, N., Ntalla, I., Karthikeyan, S., Cook, J., Chen, L., Mifsud, B., Yao, C., Kraja, A. T., Cartwright, J. H., Hellwege, J. N., Giri, A., Tragante, V., ... Howson, J. M. M. (2020). Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. *Nature Genetics*, 52(12), 1314-1332. <https://doi.org/10.1038/s41588-020-00713-x>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals

Praveen Surendran^{1,2,3,4,266}, Elena V. Feofanova^{5,266}, Najim Lahrouchi^{6,7,8,266}, Ioanna Ntalla^{9,266}, Savita Karthikeyan^{1,266}, James Cook¹⁰, Lingyan Chen¹, Borbala Mifsud^{9,11}, Chen Yao^{12,13}, Aldi T. Kraja¹⁴, James H. Cartwright⁹, Jacklyn N. Hellwege¹⁵, Ayush Giri^{15,16}, Vinicius Tragante^{17,18}, Gudmar Thorleifsson¹⁸, Dajiang J. Liu¹⁹, Bram P. Prins¹, Isobel D. Stewart²⁰, Claudia P. Cabrera^{9,21}, James M. Eales²², Artur Akbarov²², Paul L. Auer²³, Lawrence F. Bielak²⁴, Joshua C. Bis²⁵, Vickie S. Braithwaite^{20,26,27}, Jennifer A. Brody²⁵, E. Warwick Daw¹⁴, Helen R. Warren^{9,21}, Fotios Drenos^{28,29}, Sune Fallgaard Nielsen³⁰, Jessica D. Faul³¹, Eric B. Fauman³², Cristiano Fava^{33,34}, Teresa Ferreira³⁵, Christopher N. Foley^{1,36}, Nora Franceschini³⁷, He Gao^{38,39}, Olga Giannakopoulou^{9,40}, Franco Giulianini⁴¹, Daniel F. Gudbjartsson^{18,42}, Xiuqing Guo⁴³, Sarah E. Harris^{44,45}, Aki S. Havulinna^{45,46}, Anna Helgadottir¹⁸, Jennifer E. Huffman⁴⁷, Shih-Jen Hwang^{48,49}, Stavroula Kanoni^{9,50}, Jukka Kontto⁴⁶, Martin G. Larson^{51,52}, Ruifang Li-Gao⁵³, Jaana Lindström⁴⁶, Luca A. Lotta²⁰, Yingchang Lu^{54,55}, Jian'an Luan²⁰, Anubha Mahajan^{56,57}, Giovanni Malerba⁵⁸, Nicholas G. D. Masca^{59,60}, Hao Mei⁶¹, Cristina Menni⁶², Dennis O. Mook-Kanamori^{53,63}, David Mosen-Ansorena³⁸, Martina Müller-Nurasyid^{64,65,66}, Guillaume Paré⁶⁷, Dirk S. Paul^{1,2,68}, Markus Perola^{46,69}, Alaitz Poveda⁷⁰, Rainer Rauramaa^{71,72}, Melissa Richard⁷³, Tom G. Richardson⁷⁴, Nuno Sepúlveda^{75,76}, Xueling Sim^{77,78}, Albert V. Smith^{79,80,81}, Jennifer A. Smith^{24,31}, James R. Staley^{1,74}, Alena Stanáková⁸², Patrick Sulem¹⁸, Sébastien Thériault^{83,84}, Unnur Thorsteinsdottir^{18,80}, Stella Trompet^{85,86}, Tibor V. Varga⁷⁰, Digna R. Velez Edwards⁸⁷, Giovanni Veronesi⁸⁸, Stefan Weiss^{89,90}, Sara M. Willems²⁰, Jie Yao⁹¹, Robin Young^{1,92}, Bing Yu⁵, Weihua Zhang^{38,39,93}, Jing-Hua Zhao^{1,20,68}, Wei Zhao⁹⁴, Wei Zhao²⁴, Evangelos Evangelou^{38,95}, Stefanie Aeschbacher⁹⁶, Eralda Asllanaj^{97,98}, Stefan Blankenberg^{90,99,100,101}, Lori L. Bonnycastle¹⁰², Jette Bork-Jensen¹⁰³, Ivan Brandslund^{104,105}, Peter S. Braund^{59,60}, Stephen Burgess^{1,36,68}, Kelly Cho^{106,107,108}, Cramer Christensen¹⁰⁹, John Connell¹¹⁰, Renée de Mutser⁵³, Anna F. Dominiczak¹¹¹, Marcus Dörr^{90,112}, Gudny Eiriksdottir⁷⁹, Aliko-Eleni Farmaki^{113,114}, J. Michael Gaziano^{106,107,108}, Niels Grarup¹⁰³, Megan L. Grove-Gaona⁵, Göran Hallmans¹¹⁵, Torben Hansen¹⁰³, Christian T. Have¹⁰³, Gerardo Heiss³⁷, Marit E. Jørgensen¹¹⁶, Pekka Jousilahti⁴⁶, Eero Kajantie^{46,117,118,119}, Mihir Kamat^{1,68}, AnneMari Käräjämäki^{120,121}, Fredrik Karpe^{57,122}, Heikki A. Koistinen^{46,123,124}, Csaba P. Kovesdy¹²⁵, Kari Kuulasmaa⁴⁶, Tiina Laatikainen^{46,126}, Lars Lannfelt¹²⁷, I-Te Lee^{128,129,130,131}, Wen-Jane Lee^{132,133}, LifeLines Cohort Study, Allan Linneberg^{134,135}, Lisa W. Martin¹³⁶, Marie Moitry¹³⁷, Girish Nadkarni⁵⁴, Matt J. Neville^{57,122}, Colin N. A. Palmer¹³⁸, George J. Papanicolaou¹³⁹, Oluf Pedersen¹⁰³, James Peters^{1,3,140}, Neil Poulter¹⁴¹, Asif Rasheed¹⁴², Katrine L. Rasmussen³⁰, N. William Rayner^{56,57}, Reedik Mägi¹⁴³, Frida Renström^{70,115}, Rainer Rettig^{90,144}, Jacques Rossouw¹⁴⁵, Pamela J. Schreiner¹⁴⁶, Peter J. Sever¹⁴¹, Emil L. Sigurdsson^{147,148}, Tea Skaaby¹⁴⁹, Yan V. Sun¹⁵⁰, Johan Sundstrom¹⁵¹, Gudmundur Thorgeirsson^{18,80,152}, Tõnu Esko^{143,153}, Elisabetta Trabetti⁵⁸, Philip S. Tsao¹⁵⁴, Tiinamaija Tuomi^{155,156,157}, Stephen T. Turner¹⁵⁸, Ioanna Tzoulaki^{38,95,265}, Ilonca Vaartjes^{159,160}, Anne-Claire Vergnaud³⁸, Cristen J. Willer^{161,162,163}, Peter WF. Wilson¹⁶⁴, Daniel R. Witte^{165,166,167}, Ekaterina Yonova-Doing¹, He Zhang¹⁶¹, Naheed Aliya¹⁶⁸, Peter Almgren¹⁶⁹, Philippe Amouyel^{170,171,172,173}, Folkert W. Asselbergs^{17,174,175}, Michael R. Barnes^{9,21}, Alexandra I. Blakemore^{28,176}, Michael Boehnke⁷⁷, Michiel L. Bots^{159,160}, Erwin P. Bottinger⁵⁴, Julie E. Buring^{41,177}, John C. Chambers^{38,39,93,178,179}, Yii-Der Ida Chen⁹¹, Rajiv Chowdhury¹, David Conen^{83,180}, Adolfo Correa¹⁸¹, George Davey Smith⁷⁴, Rudolf A. de Boer¹⁸², Ian J. Deary^{44,183}, George Dedoussis¹¹³, Panos Deloukas^{9,21,50,184}, Emanuele Di Angelantonio^{1,2,3,68,185,186}, Paul Elliott^{38,39,187,188}, EPIC-CVD, EPIC-InterAct, Stephan B. Felix^{90,112}, Jean Ferrières¹⁸⁹, Ian Ford⁹², Myriam Fornage^{5,73}, Paul W. Franks^{70,190,191,192}, Stephen Franks¹⁹³, Philippe Frossard¹⁴², Giovanni Gambaro¹⁹⁴, Tom R. Gaunt⁷⁴, Leif Groop^{195,196}, Vilmundur Gudnason^{79,80}, Tamara B. Harris¹⁹⁷, Caroline Hayward⁴⁷, Branwen J. Hennig^{27,198}, Karl-Heinz Herzig^{199,200}, Erik Ingelsson^{201,202,203,204}, Jaakko Tuomilehto^{46,205,206,207}, Marjo-Riitta Jarvelin^{28,38,39,208}, J. Wouter Jukema^{86,209}, Sharon L. R. Kardinaal²⁴, Frank Kee²¹⁰, Jaspal S. Kooner^{39,93,179,211}, Charles Kooperberg²¹², Lenore J. Launer¹⁹⁷, Lars Lind¹⁵¹, Ruth J. F. Loos^{54,213}, Abdulla al Shafi Majumder²¹⁴, Markku Laakso¹²⁶, Mark I. McCarthy^{56,57,122}, Olle Melander³⁴, Karen L. Mohlke²¹⁵, Alison D. Murray²¹⁶, Børge Grønne Nordestgaard³⁰, Marju Orho-Melander³⁴, Chris J. Packard²¹⁷, Sandosh Padmanabhan²¹⁸, Walter Palmas²¹⁹, Ozren Polasek²²⁰, David J. Porteous^{221,222}, Andrew M. Prentice^{27,223}, Michael A. Province¹⁴, Caroline L. Relton⁷⁴, Kenneth Rice²²⁴, Paul M. Ridker^{41,177}, Olov Rolandsson¹⁹¹, Frits R. Rosendaal⁵³, Jerome I. Rotter²²⁵, Igor Rudan²²⁶,

53 Veikko Salomaa⁴⁶, Nilesh J. Samani^{59,60}, Naveed Sattar¹¹¹, Wayne H.-H. Sheu^{128,129,227,228}, Blair H. Smith²²⁹,
54 Nicole Soranzo^{230,231,232}, Timothy D. Spector⁶², John M. Starr^{44,233}, Sebert Sylvain^{234,235,236}, Kent D.
55 Taylor²³⁷, Timo A. Lakka^{71,72,238}, Nicholas J. Timpson⁷⁴, Martin D. Tobin^{60,239}, Understanding Society
56 Scientific Group, Pim van der Harst^{240,241,242}, Peter van der Meer²⁴², Ramachandran S. Vasan^{51,243}, Niek
57 Verweij²⁴⁴, Jarmo Virtamo⁴⁶, Uwe Völker^{89,90}, David R. Weir³¹, Eleftheria Zeggini^{245,246}, Fadi J.
58 Charchar^{59,247,248}, Million Veteran Program, Nicholas J. Wareham²⁰, Claudia Langenberg²⁰, Maciej
59 Tomaszewski^{22,249}, Adam S. Butterworth^{1,2,3,68,185}, Mark J. Caulfield^{9,21}, John Danesh^{1,2,3,68,185,186}, Todd L.
60 Edwards²⁵⁰, Hilma Holm¹⁸, Adriana M. Hung²⁵¹, Cecilia M. Lindgren^{35,252,253}, Chunyu Liu²⁵⁴, Alisa K.
61 Manning^{108,255}, Andrew P. Morris^{10,252,256}, Alanna C. Morrison⁵, Christopher J. O'Donnell²⁵⁷, Bruce M.
62 Psaty^{25,258,259,260}, Danish Saleheen^{1,261,262}, Kari Stefansson^{18,80}, Eric Boerwinkle^{5,263,267}, Daniel I.
63 Chasman^{41,177,267}, Daniel Levy^{51,264,267}, Christopher Newton-Cheh^{6,7,267}, Patricia B. Munroe^{9,21,267} and Joanna
64 M. M. Howson^{1,68,265,267}

65

66

67

- 68 1. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and
69 Primary Care, University of Cambridge, Cambridge, UK.
- 70 2. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK.
- 71 3. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge,
72 Cambridge, UK.
- 73 4. Rutherford Fund Fellow, Department of Public Health and Primary Care, University of Cambridge,
74 Cambridge, UK.
- 75 5. Human Genetics Center, The University of Texas Health Science Center at Houston, Houston, TX,
76 USA.
- 77 6. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA,
78 USA.
- 79 7. Cardiovascular Research Center, Center for Genomic Medicine, Massachusetts General Hospital,
80 Boston, MA, USA.
- 81 8. Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental
82 Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
- 83 9. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen
84 Mary University of London, London, UK.
- 85 10. Department of Biostatistics, University of Liverpool, Liverpool, UK.
- 86 11. College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.
- 87 12. Framingham Heart Study, Framingham, MA, USA.
- 88 13. Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood
89 Institute, National Institutes of Health, Bethesda, MD, USA.
- 90 14. Division of Statistical Genomics, Department of Genetics and Center for Genome Sciences and
91 Systems Biology, Washington University School of Medicine, St. Louis, MO, USA.
- 92 15. Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health,
93 Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Tennessee Valley Healthcare System
94 (626)/Vanderbilt University, Nashville, TN, USA.
- 95 16. Division of Quantitative Sciences, Department of Obstetrics & Gynecology, Vanderbilt Genetics
96 Institute, Vanderbilt University Medical Center, Tennessee Valley Healthcare System (626)/Vanderbilt
97 University, Nashville, TN, USA.
- 98 17. Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht
99 University, Utrecht, The Netherlands.
- 100 18. deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
- 101 19. Institute of Personalized Medicine, Penn State College of Medicine, Hershey, PA, USA.
- 102 20. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK.

- 103 21. National Institute for Health Research Barts Cardiovascular Biomedical Research Centre, Queen
104 Mary University of London, London, UK.
- 105 22. Division of Cardiovascular Sciences, Faculty of Medicine, Biology and Health, University of
106 Manchester, Manchester, UK.
- 107 23. Joseph J. Zilber School of Public Health, University of Wisconsin, Milwaukee, WI, USA.
- 108 24. Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.
- 109 25. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle,
110 WA, USA.
- 111 26. MRC Nutrition and Bone Health Group, University of Cambridge, Cambridge, UK. Formerly, MRC
112 Human Nutrition Research, Cambridge, UK.
- 113 27. MRC Unit The Gambia at London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
- 114 28. Department of Life Sciences, College of Health and Life Sciences, Brunel University London,
115 London, UK.
- 116 29. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College
117 London, London, UK.
- 118 30. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University
119 Hospital, Herlev, Denmark.
- 120 31. Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI,
121 USA.
- 122 32. Internal Medicine Research Unit, Pfizer, Cambridge MA, USA.
- 123 33. Department of Medicine, University of Verona, Verona, Italy.
- 124 34. Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
- 125 35. The Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of
126 Oxford, Oxford, UK.
- 127 36. MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
- 128 37. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina,
129 Chapel Hill, NC, USA.
- 130 38. Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of
131 Public Health, Imperial College London, London, UK.
- 132 39. National Institute for Health Research (NIHR) Imperial Biomedical Research Centre, Imperial
133 College London, London, UK.
- 134 40. Centre for Genomic Health, Queen Mary University of London, London, UK.
- 135 41. Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- 136 42. School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
- 137 43. The Institute for Translational Genomics and Population Sciences, Department of Pediatrics,
138 LABioMed at Harbor-UCLA Medical Center, Torrance, CA, USA.
- 139 44. Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.
- 140 45. Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK.
- 141 46. Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland.
- 142 47. MRC Human Genetics Unit, IGMM, University of Edinburgh, Western General Hospital,
143 Edinburgh, UK.
- 144 48. Population Sciences, Branch, National Heart, Lung, and Blood Institute, National Institute of Health,
145 Bethesda, MD, USA.
- 146 49. Boston University's and Boston University's and National Heart, Lung and Blood Institute's
147 Framingham Heart Study, Framingham, MA, USA.
- 148 50. Centre for Genomic Health, Life Sciences, Queen Mary University of London, London, UK.
- 149 51. Boston University's and National Heart, Lung and Blood Institute's Framingham Heart Study,
150 Framingham, MA, USA.
- 151 52. Biostatistics Department, Boston University School of Public Health, Boston, MA, USA.

- 152 53. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
153 54. The Charles Bronfman Institute for Personalized Medicine at Mount Sinai, Icahn School of Medicine
154 at Mount Sinai, New York, NY, USA.
155 55. Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt
156 Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
157 56. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford,
158 Oxford, UK.
159 57. Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine,
160 University of Oxford, Oxford, UK.
161 58. Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona,
162 Italy.
163 59. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
164 60. National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK.
165 61. Department of Data Science, School of Population Health, University of Mississippi Medical Center,
166 Jackson, MS, USA.
167 62. Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
168 63. Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The
169 Netherlands.
170 64. Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for
171 Environmental Health, Neuherberg, Germany.
172 65. Department of Medicine I, Ludwig-Maximilians-University Munich, Munich, Germany.
173 66. Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany.
174 67. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario,
175 Canada.
176 68. National Institute for Health Research Cambridge Biomedical Research Centre, University of
177 Cambridge and Cambridge University Hospitals, Cambridge, UK.
178 69. Clinical and Molecular Metabolism Research Program (CAMM), Faculty of Medicine, University of
179 Helsinki, Helsinki, Finland.
180 70. Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Skåne
181 University Hospital Malmö, Malmö, Sweden.
182 71. Kuopio Research Institute of Exercise Medicine, Kuopio, Finland.
183 72. Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio,
184 Finland.
185 73. Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health
186 Science Center at Houston, Houston, TX, USA.
187 74. MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School,
188 University of Bristol, Bristol, UK.
189 75. Department of Infection Biology, Faculty of Tropical and Infectious Diseases, London School of
190 Hygiene & Tropical Medicine, London, UK.
191 76. Centre of Statistics and Applications of University of Lisbon, Lisbon, Portugal, Lisbon.
192 77. Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor,
193 MI, USA.
194 78. Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
195 79. Icelandic Heart Association, Kopavogur, Iceland.
196 80. Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
197 81. Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
198 82. University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
199 83. Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

- 200 84. Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University, Quebec
201 City, Quebec, Canada.
- 202 85. Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The
203 Netherlands.
- 204 86. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
- 205 87. Vanderbilt Genetics Institute, Vanderbilt Epidemiology Center, Department of Obstetrics and
206 Gynecology, Vanderbilt University Medical Center; Tennessee Valley Health Systems VA, Nashville, TN,
207 USA.
- 208 88. Research Center in Epidemiology and Preventive Medicine, Department of Medicine and Surgery,
209 University of Insubria, Varese, Italy.
- 210 89. Interfaculty Institute for Genetics and Functional Genomics, University Medicine and University of
211 Greifswald, Greifswald, Germany.
- 212 90. DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Greifswald, Germany.
- 213 91. The Institute for Translational Genomics and Population Sciences, Department of Pediatrics,
214 LABioMed at Harbor-UCLA Medical Center, Torrance, CA, USA.
- 215 92. Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
- 216 93. Department of Cardiology, Ealing Hospital, Middlesex, UK.
- 217 94. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
- 218 95. Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina,
219 Greece.
- 220 96. Division of Cardiology, University Hospital, Basel, Switzerland.
- 221 97. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
- 222 98. Department of Epidemiology, Erasmus MC, University Medical Centre, Rotterdam, The
223 Netherlands.
- 224 99. Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg,
225 Germany.
- 226 100. University Medical Center Hamburg Eppendorf, Hamburg, Germany.
- 227 101. German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Hamburg,
228 Germany.
- 229 102. Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute,
230 NIH, Bethesda, MD, USA.
- 231 103. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical
232 Sciences, University of Copenhagen, Copenhagen, Denmark.
- 233 104. Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark.
- 234 105. Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
- 235 106. Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston
236 Healthcare System, Boston, MA, USA.
- 237 107. Division of Aging, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
- 238 108. Department of Medicine, Harvard Medical School, Boston, MA, USA.
- 239 109. Medical department, Lillebaelt Hospital, Vejle, Denmark.
- 240 110. University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.
- 241 111. Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences,
242 University of Glasgow, Glasgow, UK.
- 243 112. Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
- 244 113. Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio
245 University, Athens, Greece.
- 246 114. Department of Population Science and Experimental Medicine, Institute of Cardiovascular Science,
247 University College London, London, UK.
- 248 115. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

- 249 116. Steno Diabetes Center, Copenhagen, Gentofte, Denmark.
- 250 117. PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, Finland.
- 251 118. Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology,
252 Trondheim, Norway.
- 253 119. Hospital for Children and Adolescents, Helsinki University Central Hospital and University of
254 Helsinki, Helsinki, Finland.
- 255 120. Department of Primary Health Care, Vaasa Central Hospital, Vaasa, Finland.
- 256 121. Diabetes Center, Vaasa Health Care Center, Vaasa, Finland.
- 257 122. Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, UK.
- 258 123. Department of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki,
259 Finland.
- 260 124. Minerva Foundation Institute for Medical Research, Helsinki, Finland.
- 261 125. Nephrology Section, Memphis VA Medical Center, Memphis, TN, USA.
- 262 126. Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio,
263 Finland.
- 264 127. Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
- 265 128. Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans
266 General Hospital, Taichung, Taiwan.
- 267 129. School of Medicine, National Yang-Ming University, Taipei, Taiwan.
- 268 130. School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- 269 131. College of Science, Tunghai University, Taichung, Taiwan.
- 270 132. Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
- 271 133. Department of Social Work, Tunghai University, Taichung, Taiwan.
- 272 134. Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, The Capital
273 Region, Copenhagen, Denmark.
- 274 135. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of
275 Copenhagen, Copenhagen, Denmark.
- 276 136. George Washington University School of Medicine and Health Sciences, Washington DC, USA.
- 277 137. Department of Public health, Strasbourg University hospital, University of Strasbourg, Strasbourg,
278 France.
- 279 138. Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee,
280 UK.
- 281 139. Epidemiology Branch, NHLBI, Bethesda, MD, USA.
- 282 140. Department of Immunology and Inflammation, Imperial College London, London, UK.
- 283 141. International Centre for Circulatory Health, Imperial College London, London, UK.
- 284 142. Centre for Non-Communicable Diseases, Karachi, Pakistan.
- 285 143. Institute of Genomics, University of Tartu, Tartu, Estonia.
- 286 144. Institute of Physiology, University Medicine Greifswald, Karlsburg, Germany.
- 287 145. Division of Cardiovascular Sciences, NHLBI, Bethesda, MD, USA.
- 288 146. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN,
289 USA.
- 290 147. Department of Family Medicine, University of Iceland, Reykjavik, Iceland.
- 291 148. Development Centre for Primary Health Care in Iceland, Iceland.
- 292 149. Center for Clinical Research and Disease Prevention, Bispebjerg and Frederiksberg Hospital, The
293 Capital Region, Copenhagen, Denmark.
- 294 150. Department of Epidemiology, Emory University Rollins School of Public Health; Department of
295 Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA.
- 296 151. Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

297 152. Department of Internal Medicine, Division of Cardiology, Landspítali - The National University
298 Hospital of Iceland, Reykjavik, Iceland.

299 153. Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.

300 154. VA Palo Alto Health Care System, Division of Cardiovascular Medicine, Stanford University School
301 of Medicine, Stanford, CA, USA.

302 155. Folkhälsan Research Centre, Helsinki, Finland.

303 156. Department of Endocrinology, Helsinki University Central Hospital, Helsinki, Finland.

304 157. Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre,
305 Malmö, Sweden. Institute for Molecular Medicine Helsinki (FIMM), Helsinki University, Helsinki, Finland.

306 158. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.

307 159. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University
308 of Utrecht, University of Utrecht, The Netherlands.

309 160. Center for Circulatory Health, University Medical Center Utrecht, University of Utrecht, The
310 Netherlands.

311 161. Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan,
312 Ann Arbor, MI, USA.

313 162. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor,
314 MI, USA.

315 163. Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA.

316 164. Atlanta VAMC and Emory Clinical Cardiovascular Research Institute, Atlanta, GA, USA.

317 165. Department of Public Health, Aarhus University, Aarhus, Denmark.

318 166. Danish Diabetes Academy, Odense, Denmark.

319 167. Steno Diabetes Center Aarhus, Aarhus, Denmark.

320 168. International Centre for Diarrhoeal Disease Research, Bangladesh (icDDR,b), Mohakhali, Dhaka,
321 Bangladesh.

322 169. Dep of Medicine, Lund University, Malmö, Sweden.

323 170. Univ. Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées
324 au vieillissement, Lille, France.

325 171. Inserm, U1167, Lille, France.

326 172. CHU Lille, U1167, Lille, France.

327 173. Institut Pasteur de Lille, U1167, Lille, France.

328 174. Health Data Research UK, Institute of Health Informatics, University College London, London, UK.

329 175. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College
330 London, London, UK.

331 176. Section of Investigative Medicine, Imperial College London, Hammersmith Hospital Campus,
332 London, UK.

333 177. Harvard Medical School, Boston, MA, USA.

334 178. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.

335 179. Imperial College Healthcare NHS Trust, London, UK.

336 180. Cardiovascular Research Institute Basel, Basel, Switzerland.

337 181. Jackson Heart Study, Department of Medicine, University of Mississippi Medical Center, Jackson,
338 MS, USA.

339 182. University of Groningen, University Medical Center Groningen, Department of Cardiology,
340 Groningen, The Netherlands.

341 183. Department of Psychology, University of Edinburgh, Edinburgh, UK.

342 184. Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-
343 HD), King Abdulaziz University, Jeddah, Saudi Arabia.

344 185. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and
345 Genomics, University of Cambridge, Cambridge, UK.

- 346 186. Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK.
347 187. Health Data Research UK – London at Imperial College London, London, UK.
348 188. UKDRI, Dementia Research Institute at Imperial College London, London, UK.
349 189. Department of Cardiology and Department of Epidemiology, INSERM UMR 1027, Toulouse
350 University Hospital, Toulouse, France.
351 190. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
352 191. Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden.
353 192. Oxford Center for Diabetes, Endocrinology & Metabolism, Radcliff Department of Medicine,
354 University of Oxford, Oxford, UK.
355 193. Institute of Reproductive & Developmental Biology, Imperial College London, London, UK.
356 194. Division of Nephrology, Department of Medicine, University of Verona, Verona, Italy.
357 195. Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre,
358 Malmö, Sweden.
359 196. Institute for Molecular Medicine Helsinki (FIMM), Helsinki University, Helsinki, Finland.
360 197. Laboratory of Epidemiology and Population Sciences, National Institute of Aging, Bethesda, MD,
361 USA.
362 198. Wellcome Trust, London, UK.
363 199. Institute of Biomedicine, Medical Research Center (MRC), University of Oulu, and University
364 Hospital Oulu, Oulu, Finland.
365 200. Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan,
366 Poland.
367 201. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of
368 Medicine, Stanford, CA, USA.
369 202. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala
370 University, Uppsala, Sweden.
371 203. Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
372 204. Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.
373 205. Department of Public Health, University of Helsinki, Helsinki, Finland.
374 206. Saudi Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
375 207. National Institute of Public Health, Madrid, Spain.
376 208. Unit of Primary Care, Oulu University Hospital, Oulu, Finland.
377 209. Netherlands Heart Institute, Utrecht, The Netherlands, Utrecht, The Netherlands.
378 210. Centre for Public Health, Queens University Belfast, Belfast, UK.
379 211. National Heart and Lung Institute, Imperial College London, London, UK.
380 212. Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA, USA.
381 213. The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai,
382 New York, NY, USA.
383 214. National Institute of Cardiovascular Diseases, Sher-e-Bangla Nagar, Dhaka, Bangladesh.
384 215. Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
385 216. The Institute of Medical Sciences, Aberdeen Biomedical Imaging Centre, University of Aberdeen,
386 Aberdeen, UK.
387 217. University of Glasgow, Glasgow, UK.
388 218. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
389 219. Department of Medicine, Columbia University Medical Center, New York, NY, USA.
390 220. Department of Public Health, University of Split School of Medicine, Split, Croatia.
391 221. Centre for Genomic and Experimental Medicine, Institute of Genetics & Molecular Medicine,
392 University of Edinburgh, Western General Hospital, Edinburgh, UK.
393 222. Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, The
394 University of Edinburgh, Edinburgh, UK.

- 395 223. MRC International Nutrition Group at London School of Hygiene & Tropical Medicine, London,
396 UK.
- 397 224. Department of Biostatistics, University of Washington, Seattle, WA, USA.
- 398 225. Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and
399 Medicine, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, USA.
- 400 226. Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics,
401 University of Edinburgh, Edinburgh, UK.
- 402 227. School of Medicine, National Defense Medical Center, Taipei, Taiwan.
- 403 228. Institute of Medical Technology, National Chung-Hsing University, Taichung, Taiwan.
- 404 229. Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of
405 Dundee, Dundee, UK.
- 406 230. Department of Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton,
407 Cambridge, UK.
- 408 231. Department of Haematology, University of Cambridge, Cambridge, UK.
- 409 232. The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor
410 Health and Genomics at the University of Cambridge, Cambridge, UK.
- 411 233. Alzheimer Scotland Research Centre, University of Edinburgh, Edinburgh, UK.
- 412 234. Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.
- 413 235. Biocenter Oulu, University of Oulu, Oulu, Finland.
- 414 236. Department of Genomics of Complex Diseases, School of Public Health, Imperial College London,
415 London, UK.
- 416 237. Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research
417 Institute at Harbor/UCLA Medical Center, Torrance, CA, USA.
- 418 238. Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio Campus, Kuopio,
419 Finland.
- 420 239. Department of Health Sciences, University of Leicester, Leicester, UK.
- 421 240. University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen,
422 The Netherlands.
- 423 241. Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The
424 Netherlands.
- 425 242. University of Groningen, University Medical Center Groningen, Department of Cardiology,
426 Groningen, The Netherlands.
- 427 243. Boston University Schools of Medicine and Public Health, Boston, MA, USA.
- 428 244. University Medical Center Groningen, Groningen, The Netherlands.
- 429 245. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
- 430 246. Institute of Translational Genomics, Helmholtz Zentrum München – German Research Center for
431 Environmental Health, Neuherberg, Germany.
- 432 247. School of Health and Life Sciences, Federation University Australia, Ballarat, Victoria, Australia.
- 433 248. Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia.
- 434 249. Division of Medicine, Manchester University NHS Foundation Trust, Manchester Academic Health
435 Science Centre, Manchester, UK.
- 436 250. Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health,
437 Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Tennessee Valley Healthcare System
438 (626)/Vanderbilt University, Nashville, TN, USA.
- 439 251. VA Tennessee Valley Healthcare System, Division of Nephrology & Hypertension, Department of
440 Medicine, Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, TN,
441 USA.
- 442 252. Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

- 443 253. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA,
444 USA.
- 445 254. Boston University School of Public Health, Boston, MA, USA.
- 446 255. Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA.
- 447 256. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester,
448 Manchester, UK.
- 449 257. VA Boston Healthcare, Section of Cardiology and Department of Medicine, Brigham and Women's
450 Hospital, Harvard Medical School, Boston, MA, USA.
- 451 258. Department of Epidemiology, University of Washington, Seattle, WA, USA.
- 452 259. Department of Health Services, University of Washington, Seattle, WA, USA.
- 453 260. Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
- 454 261. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of
455 Pennsylvania, Philadelphia, PA, USA.
- 456 262. Center for Non-Communicable Diseases, Karachi, Pakistan.
- 457 263. Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
- 458 264. Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institute of Health,
459 Bethesda, MD, USA.
- 460 265. Department of Genetics, Novo Nordisk Research Centre Oxford, Oxford, UK.

461

462 *Current address (if different to the affiliations)

463 Mark McCarthy: Genentech, South San Francisco, CA, USA.

464

465 266. These authors contributed equally to this work.

466 267. These authors jointly supervised the work.

467

468 Corresponding authors:

469 Joanna M. M. Howson: JMMHowson@gmail.com

470 Patricia B. Munroe: P.B.Munroe@qmul.ac.uk

471

472

473 **Genetic studies of blood pressure (BP) to date have mainly analyzed common variants (minor allele**
474 **frequency, MAF > 0.05). In a meta-analysis of up to >1.3 million participants, we discovered 106 new**
475 **BP-associated genomic regions and 87 rare (MAF ≤ 0.01) variant BP associations ($P < 5 \times 10^{-8}$), of which**
476 **32 were in new BP-associated loci and 55 were independent BP-associated SNVs within known BP-**
477 **associated regions. Average effects of rare variants (44% coding) were ~8 times larger than common**
478 **variant effects and indicate potential candidate causal genes at new and known loci (e.g. *GATA5*,**
479 ***PLCB3*). BP-associated variants (including rare and common) were enriched in regions of active**
480 **chromatin in fetal tissues, potentially linking fetal development with BP regulation in later life.**
481 **Multivariable Mendelian randomization suggested possible inverse effects of elevated systolic and**
482 **diastolic BP on large artery stroke. Our study demonstrates the utility of rare variant analyses for**
483 **identifying candidate genes and the results highlight potential therapeutic targets.**

489 Increased blood pressure (BP) is a major risk factor for cardiovascular disease (CVD) and related disability
490 worldwide¹. Its complications are estimated to account for ~10.7 million premature deaths annually¹.
491 Genome-wide association studies (GWAS) and exome array-wide association studies (EAWAS) have
492 identified over 1,000 BP-associated single nucleotide variants (SNVs)²⁻¹⁹ for this complex, heritable,
493 polygenic trait. The majority of these are common SNVs (MAF > 0.05) with small effects on BP. Most
494 reported associations involve non-coding SNVs, and due to linkage disequilibrium (LD) between common
495 variants, these studies provide limited insights into the specific causal genes through which their effects are
496 mediated. The exome array was designed to facilitate analyses of rare coding variants (MAF ≤ 0.01) with
497 potential functional consequences. Over 80% of SNVs on the array are rare, ~6% are low frequency (0.01 <
498 MAF ≤ 0.05), and ~80% are missense, *i.e.* the variants implicate a candidate causal gene through changes to
499 the amino acid sequence. Previously, using the exome array, we identified four BP loci with rare variant
500 associations (*RBM47*, *COL21A1*, *RRAS*, *DBH*)^{13,14} and a rare nonsense BP variant in *ENPEP*, encoding an
501 aminopeptidase with a known role in BP regulation¹³. These findings confirmed the utility of rare variant
502 studies for identifying potential causal genes. These rare variant associations had larger effects on BP
503 (typically ~1.5 mmHg per minor allele) than common variants identified by previous studies (typically ~0.5
504 mmHg per minor allele), many of which had power to detect common variants with large effects. Here, we
505 combine the studies from our previous two exome array reports with additional studies, including the UK
506 Biobank (UKBB) study, to analyze up to ~1.319 million participants and investigate the role of rare SNVs in
507 BP regulation.

511 Results

512 We performed an EAWAS and a rare variant GWAS (RV-GWAS) of imputed and genotyped SNVs to
513 identify variants associated with BP traits, hypertension (HTN), and inverse normal transformed systolic BP
514 (SBP), diastolic BP (DBP), and pulse pressure (PP) using (i) single variant analysis and (ii) a gene-based test
515 approach. An overview of our study design for both the EAWAS and for the RV-GWAS is provided in
516 Figure 1.

517
518 **Blood pressure associations in the EAWAS.** We performed a discovery meta-analysis to identify genetic
519 variants associated with BP in up to ~1.32 million individuals. To achieve this, we first performed a meta-
520 analysis of 247,315 exome array variants in up to 92 studies (870,217 participants, including UKBB) for
521 association with BP, Stage 1 (Fig. 1, Methods, and Supplementary Information). There were 362 BP loci
522 known at the time of the analysis (Supplementary Table 1), 240 of which were covered on the exome array.
523 To improve statistical power for discovery for a subset of variants significant in Stage 1 at $P < 5 \times 10^{-8}$
524 outside of the known BP regions (Supplementary Table 1a), we requested summary association statistics
525 from three additional studies (Million Veteran Program (MVP), deCODE, and GENOA). We then
526 performed meta-analyses of the three data request studies and Stage 1 results to discover novel variants
527 associated with BP. In total, 343 SNVs (200 genomic regions; Methods) were associated ($P < 5 \times 10^{-8}$) with
528 one or more BP traits in the Stage 2 single variant European (EUR) EAWAS meta-analyses involving up to
529 ~1.168 million individuals (Table 1, Fig. 2, Supplementary Table 2, and Supplementary Information). A
530 further seven SNVs (seven genomic regions) were only associated ($P < 5 \times 10^{-8}$) in the pan-ancestry (PA)
531 meta-analyses of ~1.319 million individuals (Supplementary Table 2). All 350 SNV-BP associations were
532 novel at the time of analysis (204 loci), 220 have subsequently been reported^{20,21}, and 130 SNVs (99 loci)
533 remain novel, including nine rare and 13 low-frequency SNVs (Fig. 2, Supplementary Table 2,
534 Supplementary Fig. 1).

535 All nine novel rare BP-associated SNVs identified in the EAWAS were conditionally independent of
536 common variant associations within the respective regions (Supplementary Table 3) using the multi-SNP-
537 based conditional and joint association analysis (GCTA v1.91.4)²² with the Stage 1 EUR EAWAS results

(Methods and Supplementary Table 4). In addition to the rare variants, there were 147 additional distinct ($P < 1 \times 10^{-6}$) common SNV-BP associations (46% were missense variants), and 18 distinct low-frequency SNVs (89% were missense). Approximately 59% of the distinct BP-associated SNVs were coding or in strong LD ($r^2 > 0.8$) with coding SNVs. In total, 42 of the 99 novel loci had two or more distinct BP-associated SNVs in the conditional analyses. Of the 50 loci that were previously identified using UKBB^{16,17} and were on the exome array, 43 replicated at $P < 0.001$ (Bonferroni correction for 50 known variants) in samples independent of the original discovery (Supplementary Table 5).

Blood pressure associations from EUR RV-GWAS. We tested a further 29,454,346 (29,404,959 imputed and 49,387 genotyped) rare SNVs for association with BP in 445,360 UKBB participants²³ using BOLT-LMM²⁴ (Fig. 1 and Methods). The SNVs analyzed as part of the EAWAS were not included in the RV-GWAS. Similar to EAWAS, within RV-GWAS we performed a single discovery meta-analysis to identify rare SNVs associated with BP. In Stage 1 (UKBB), 84 rare SNVs outside of the known BP loci (at the time of our analyses) were associated with one or more BP traits at $P < 1 \times 10^{-7}$ (Supplementary Table 6). Additional data were requested from MVP for the 84 BP-associated SNVs in up to 225,112 EUR from the MVP, and 66 were available. Meta-analysis of Stage 1 (UKBB) and results obtained from MVP were performed for novel rare variant discovery. We identified 23 unique rare SNVs associated with one or more BP traits ($P < 5 \times 10^{-8}$) with consistent direction of effects in a meta-analysis of UKBB and MVP (min $P_{\text{heterogeneity}} = 0.02$) (Table 1, Fig. 2, Supplementary Table 7, and Supplementary Fig. 1). Two of the SNVs, rs55833332 (p.Arg35Gly) in *NEK7* and rs200383755 (p.Ser19Trp) in *GATA5*, were missense. Eleven rare SNVs were genome-wide significant in UKBB alone but were not available in MVP and await further support in independent studies (Supplementary Table 7).

Rare and low frequency variant associations at established BP loci. It is difficult to prioritize candidate genes at common variant loci for functional follow up. We believe analysis of rare (MAF < 0.01) and very low frequency coding variants (MAF ≤ 0.02) in known loci may provide further support for or identify a candidate causal gene at a locus. Twelve of the 240 BP-associated regions had one or more conditionally

565 independent rare variant associations ($P < 10^{-6}$ in the GCTA joint model of the EUR Stage 1 EAWAS;
566 Methods, Table 2, and Supplementary Table 3). A further nine loci had one or more conditionally
567 independent BP-associated SNVs with $MAF \leq 0.02$ (Table 2 and Supplementary Table 8). In total, 183
568 SNVs (rare and common) across 110 known loci were not identified previously.

569 We used FINEMAP²⁵ to fine-map 315 loci known at the time of our analysis and available in UKBB
570 GWAS, which provides dense coverage of genomic variation not available on the exome array. Of these, 36
571 loci had one or more conditionally independent rare variant associations (Supplementary Table 8), and 251
572 loci had multiple common variants associations. We also replicated rare variant associations that we
573 reported previously^{13,14} at *RBM47*, *COL21A1*, *RRAS*, and *DBH* ($P < 5 \times 10^{-5}$) in UKBB (independent of
574 prior studies). Overall, from both FINEMAP and GCTA, we identified 40 loci with one or more rare SNV
575 associations, independent of previously reported common variant associations (Table 3, Fig. 2,
576 Supplementary Table 8, and Supplementary Information).

577 We note that, of 256 known variants identified without UKBB participants (Supplementary Table
578 1a), 229 replicated at $P < 1.95 \times 10^{-4}$ (Bonferroni adjusted for 256 variants) in UKBB.

579
580 **Gene-based tests to identify BP-associated genes.** To test whether rare variants in aggregate affect BP
581 regulation, we performed gene-based tests for SBP, DBP, and PP using SKAT²⁶
582 (<https://genome.sph.umich.edu/wiki/RareMETALS>), including SNVs with $MAF \leq 0.01$ that were predicted
583 by VEP²⁷ to have high or moderate impact (Methods). We performed separate analyses within the Stage 1
584 EAWAS and the UKBB RV-GWAS. Six genes in the EAWAS (*FASTKD2*, *CPXM2*, *CENPJ*, *CDC42EP4*,
585 *OTOP2*, *SCARF2*) and two in the RV-GWAS (*FRY*, *CENPJ*) were associated with BP ($P < 2.5 \times 10^{-6}$,
586 Bonferroni adjusted for ~20,000 genes) and were outside known and new BP loci (Supplementary Tables 1
587 and 9). To ensure these associations were not attributable to a single (sub-genome-wide significant) rare
588 variant, we also performed SKAT tests conditioning on the variant with the smallest P -value in the gene
589 (Methods and Supplementary Table 9). *FRY* had the smallest conditional P -value ($P = 0.0004$), but did not
590 pass our pre-determined conditional significance threshold (conditional SKAT $P \leq 0.0001$; Methods),

591 suggesting that all gene associations are due to single (sub-genome-wide significant) rare variants and not
592 due to the aggregation of multiple rare variants.

593 Amongst the known loci, five genes (*NPR1*, *DBH*, *COL21A1*, *NOX4*, *GEM*) were associated with BP
594 due to multiple rare SNVs independent of the known common variant associations (conditional $P \leq 1 \times 10^{-5}$;
595 Methods, Supplementary Information, and Supplementary Table 9) confirming the findings in the single
596 variant conditional analyses above (Supplementary Table 8).

597 We also performed gene-based tests using a $MAF \leq 0.05$ threshold to assess sensitivity to the $MAF \leq$
598 0.01 threshold. The results were concordant with the $MAF \leq 0.01$ threshold findings, and two new genes
599 (*PLCB3* and *CEP120*) were associated with BP due to multiple SNVs and were robust to conditioning on
600 the top SNV in each gene (Supplementary Information and Supplementary Table 9).

601
602 **Rare variant BP associations.** In total, across the EAWAS and the RV-GWAS, there were 32 new BP-
603 associated rare variants spanning 18 new loci (Table 1 and Fig. 2). Of these 32, five (representing five loci)
604 were genome-wide significant for HTN, 22 (ten loci) for SBP, 14 (six loci) for DBP, and 15 (ten loci) for PP
605 (Supplementary Tables 1, 2, 3, 6, and 7). Ten of the new rare variants were missense. Within previously
606 reported loci, there were 55 independent rare-variant associations (representing 40 loci) from either the
607 EAWAS or RV-GWAS, making a total of 87 independent rare BP-associated SNVs. We identified 45 BP-
608 associated genes, eight of which were due to multiple rare variants and independent of common variant
609 associations ($P < 1 \times 10^{-4}$, Methods). Twenty-one rare variants were located within regulatory elements (e.g.
610 enhancers), highlighting genetic influence on BP levels through gene expression (Fig. 2). The rare variants
611 contributed to BP variance explained (Supplementary Information).

612 Power calculations are provided in the Supplementary Information and show that our study had 80%
613 power to detect an effect of 0.039 SD for a $MAF = 0.01$ (Extended Data Fig. 1). As anticipated, given
614 statistical power, some rare variants displayed larger effects on BP regulation than common variants (Fig. 2
615 and Supplementary Tables 3, 7, and 8); mean effects of rare SNVs for SBP and DBP were ~ 7.5 times larger
616 than common variants (mean effect ~ 0.12 SD/minor allele for rare SNVs, ~ 0.035 SD/minor allele for low-
617 frequency and ~ 0.016 SD/minor allele for common SNVs) and for PP were 8.5 times larger for rare variants

618 compared to common (mean effect ~ 0.135 SD/minor allele for rare SNVs, ~ 0.04 SD/minor allele for low-
619 frequency and ~ 0.016 SD/minor allele for common SNVs). Our study was exceptionally well-powered to
620 detect common variants (MAF > 0.05) with similarly large effects but found none, consistent with earlier BP
621 GWAS and genetic studies of some other common complex traits^{28,29,36}.

622
623 **Overlap of rare BP associations with monogenic BP genes.** Twenty-four genes are reported in ClinVar to
624 cause monogenic conditions with hypertension or hypotension as a primary phenotype. Of these, three
625 (*NR3C2*, *AGT*, *PDE3A*) were associated with BP in SKAT tests in the EAWAS ($P < 0.002$, Bonferroni
626 adjusted for 24 tests; Supplementary Table 10). These genes also had genome-wide significant SNV-BP
627 associations in the EAWAS and/or RV-GWAS (Supplementary Table 10).

628
629 **Functional annotation of rare BP-associated SNVs.** None of the BP-associated rare SNVs (from known
630 or novel loci) had been previously reported as expression quantitative trait loci (eQTL) in any tissue ($P > 5 \times$
631 10^{-8} ; Supplementary Table 11 and Methods). We used GTEx v7 data to examine in which tissues the genes
632 closest to the rare BP-SNVs were expressed (Extended Data Fig. 2 and Supplementary Table 4). Many of
633 the eQTL gene transcripts were expressed in BP-relevant tissues (e.g. kidney, heart, and arteries). We
634 observed significant enrichment (Bonferroni adjusted $P < 0.05$) in liver, kidney, heart left ventricle,
635 pancreas, and brain tissues, where the BP genes were down-regulated. In contrast, the BP genes were up-
636 regulated in tibial artery, coronary artery, and aorta (Extended Data Fig. 3). There were 33 genes at 30
637 known loci with novel BP rare variants (from Supplementary Table 12); distinct known common BP
638 variants at these known loci were eQTLs for 52% of these genes, providing additional evidence that the rare
639 variants implicate plausible candidate genes (Supplementary Table 12).

640 We tested whether genes near rare BP-associated SNVs were enriched in gene sets from Gene
641 Ontology (GO), KEGG, Mouse Genome Informatics (MGI), and Orphanet (Methods and Supplementary
642 Table 4). These (rare variant) genes from both known and novel loci were enriched in BP-related pathways
643 (Bonferroni adjusted $P < 0.05$; Methods and Supplementary Table 13), including “regulation of blood vessel
644 size” (GO) and “renin secretion” (KEGG). Genes implicated by rare SNVs at known loci were enriched in

645 “tissue remodeling” and “artery aorta” (GO). Genes implicated by rare SNVs at new BP-loci were enriched
646 in rare circulatory system diseases (that include hypertension and rare renal diseases) in Orphanet.

647

648 **Potential therapeutic insights from the rare BP-associated SNVs.** Twenty-three of the genes near rare or
649 low-frequency BP-associated variants in novel and known loci were potentially druggable as suggested by
650 the “druggable genome”³⁰ (Supplementary Information and Supplementary Tables 4 and 14). Six genes
651 (four with rare variants) are already drug targets for CVD conditions, while 15 others are in development or
652 used for other conditions. As an example, the renin-angiotensin-aldosterone system (RAAS) is one of
653 the principal homeostatic mechanisms for BP control, and aldosterone is the main mineralocorticoid
654 (secreted by adrenal glands) and binds receptors, including *NR3C2*, resulting in sodium retention by
655 the kidney and increased potassium excretion. Spironolactone is an aldosterone antagonist widely used in
656 heart failure and as a potassium-sparing anti-hypertensive medication that targets *NR3C2* (Open targets:
657 <https://www.opentargets.org>).

658

659 **Overlap of new BP-associations with metabolites.** To identify novel BP variants that are metabolite QTLs,
660 we performed *in silico* lookups of new sentinel and conditionally independent BP variants for association
661 with 913 plasma metabolites measured using the Metabolon HD4 platform in ~14,000 individuals (Methods
662 and Supplementary Table 4). Nine BP-associated variants were associated with 25 metabolites ($P < 5 \times 10^{-8}$)
663 involved in carbohydrate, lipids, cofactors and vitamins, nucleotide (cysteine), and amino acid metabolism
664 (Supplementary Table 15), while 11 were unknown.

665 We performed MR analyses to assess the influence of the 14 known metabolites (Supplementary
666 Table 15) on BP. Lower levels of 3-methylglutarylcarnitine(2) (acyl carnitines involved in long-chain fatty
667 acid metabolism in mitochondria and in leucine metabolism) were significantly associated with increased
668 DBP ($P < 0.003$, 0.05/14 metabolites; Supplementary Table 16). There was no suggestion of reverse
669 causation, i.e. BP did not affect 3-methylglutarylcarnitine(2) ($P > 0.04$; Supplementary Table 16). We
670 further tested whether the association with 3-methylglutarylcarnitine(2) was due to pleiotropic effects of

671 other metabolites in a multivariable MR framework, but found it was still causally associated with DBP
672 (Supplementary Information and Supplementary Table 16).

673

674 **New BP-associated SNVs are gene eQTLs across tissues.** Sentinel variants from 66 new BP loci were
675 associated ($P < 5 \times 10^{-8}$) with gene expression (or had $r^2 > 0.8$ in 1000G EUR with eQTLs) in publicly
676 available databases (Methods and Supplementary Tables 4 and 11). We performed colocalization for 49 of
677 the 66 BP loci (169 genes) with significant eQTLs available in GTEx v7, jointly across all 48 tissues and
678 the BP traits using HyPrColoc³¹ (Methods), to verify that the eQTL and BP-SNV associations were due to
679 the same SNVs and not due to LD or spurious pleiotropy³². The BP associations and eQTL colocalized at 17
680 BP loci with a single variant (posterior probability, PPa > 0.6), i.e. the expression and BP associations were
681 due to the same underlying causal SNV (Fig. 3 and Supplementary Table 17). A further 10 loci had PPa >
682 0.6 for colocalization of BP associations and eQTL for multiple nearby genes (Fig. 3). Colocalization
683 analyses were also performed for the 35 eQTLs in whole blood from the Framingham Heart Study, and five
684 additional loci were consistent with a shared SNV between BP and gene expression (Supplementary Table
685 17).

686 Given the central role of the kidney in BP regulation, we investigated if BP-associated SNVs from
687 the EAWAS were kidney eQTLs using TRANScriptome of renal humAn TissuE study and The Cancer
688 Genome Atlas study ($n = 285$; Methods^{33,34}). We observed significant eQTL associations ($P < 5 \times 10^{-8}$) at
689 three newly identified BP loci (*MFAP2*, *NFU1*, and *AAMDC*, which were also identified in GTEx) and six at
690 previously published loci (*ERAP1*, *ERAP2*, *KIAA0141*, *NUDT13*, *RP11-582E3.6*, and *ZNF100*;
691 Supplementary Table 18).

692

693 **New BP-associated SNVs are pQTLs.** Eighteen BP loci had sentinel variants (or were in LD with BP
694 SNVs, $r^2 > 0.8$ in 1000G EUR) that were also protein QTL (pQTL) in plasma. Across the 18 loci, BP-SNVs
695 were pQTLs for 318 proteins (Supplementary Table 19). Low-frequency SNVs in *MCL1* and *LAMA5* were
696 cis-pQTL for MCL1 and LAMA5, respectively. The BP-associated SNV, rs4660253, is a cis-pQTL and cis-
697 eQTL for *TIE1* across eight tissues in GTEx including heart (Fig. 3 and Supplementary Table 17). The DBP-

698 associated SNV, rs7776054, is in strong LD with rs9373124, which is a trans-pQTL for erythropoietin, a
699 hormone mainly synthesized by the kidneys, which has links to hypertension.

700
701 **Pathway and enrichment analyses.** The over-representation of rare and common BP SNVs in DNaseI-
702 hypersensitive sites (DHS), which mark open chromatin, was tested using GARFIELD (Methods and
703 Supplementary Table 4). The most significant enrichment in DHS hotspots for SBP-associated SNVs was in
704 fetal heart tissues, with an ~3-fold enrichment compared to ~2-fold in adult heart (Fig. 3 and Supplementary
705 Information). This difference in enrichment was also reflected in fetal muscle compared to adult muscle for
706 SBP-associated SNVs. The most significant enrichment for DBP- and PP-associated SNVs (~3-fold) was in
707 blood vessels (Fig. 3 and Supplementary Information). There was also enrichment across SBP, DBP and PP
708 in fetal and adult kidney and fetal adrenal gland. In support, complementary enrichment analyses with
709 FORGE (Methods) showed similar enrichments including in fetal kidney and fetal lung tissues (Z-score =
710 300; Supplementary Table 13 and Supplementary Information).

711
712 **Mendelian randomization with CVD.** Twenty-six new BP loci were also associated with cardiometabolic
713 diseases and risk factors in PhenoScanner³⁵ (<http://www.phenoscaner.medschl.cam.ac.uk>) (Methods, Fig.
714 3, Supplementary Information, and Supplementary Tables 4, 20, and 21). Given that BP is a key risk factor
715 for CVD, we performed Mendelian randomization (MR) analyses to assess the causal relationship of BP
716 with any stroke (AS), ischemic stroke (IS), large artery stroke (LAS), cardio-embolic stroke (CE), small
717 vessel stroke (SVS), and coronary artery disease (CAD) using all the distinct BP-associated SNVs from our
718 study (both known and new; Supplementary Table 4 and Methods). BP was a predictor of all stroke types
719 analyzed and CAD (Fig. 4 and Supplementary Fig. 4). Notably, SBP had the strongest effect on all CVD
720 phenotypes, with the most profound effect on LAS, increasing risk by >2-fold per SD (Supplementary Table
721 22). BP had weakest effect on CE, which may reflect the greater role of atrial fibrillation versus BP in CE
722 risk. Multi-variable MR analyses, including both SBP and DBP, showed that the effect of DBP attenuated to
723 zero once SBP was accounted for (consistent with observational studies³⁷), except for LAS (Fig. 4,
724 Supplementary Table 22, and Methods), where SBP/DBP had a suggestive inverse relationship, perhaps

725 reflecting arterial stiffening. An inverse relationship between DBP and stroke above age 50 years has also
726 been reported³⁷.

728 Discussion

729 Unlike most previous BP studies that focused primarily on common variant associations, the novelty of this
730 investigation is the extensive analysis of rare variants, both individually and in aggregate within a gene.
731 Many of the new rare variants are located in genes that potentially have a role in BP regulation, as evidenced
732 by support from existing mouse models (21 genes) and/or have previously been implicated in monogenic
733 disorders (11 genes) whose symptoms include hyper-/hypotension or impaired cardiac function/development
734 (Supplementary Table 12). For example, rs139600783 (p.Pro274Ser) was associated with increased DBP
735 and is located in the *ARHGAP31* gene that causes Adams-Oliver syndrome, which can be accompanied by
736 pulmonary hypertension and heart defects. A further three (of the six) genes that cause Adams-Oliver
737 syndrome are located in BP-associated loci (*DLL4*¹⁶, *DOCK6*^{13,15}, and *NOTCH1*, a new BP locus). A
738 missense variant rs200383755 (p.Ser19Trp, predicted deleterious by SIFT), located in the *GATA5*, encoding
739 a transcription factor, is associated with increased SBP and DBP. *GATA5* mutations cause congenital heart
740 defects, including bicuspid aortic valve and atrial fibrillation, while a *Gata5*-null mouse model had increased
741 SBP and DBP at 90 days³⁸.

742 Within the known loci, we detected new rare variant associations at several candidate genes, e.g. a
743 rare missense SNV rs1805090 (MAF = 0.0023) in the angiotensinogen (*AGT*) gene was associated with
744 increased BP independently of the known common variant association. *AGT* is known to have an important
745 role in BP regulation, and the variant is predicted to be among the top 1% of most deleterious substitutions³⁹.
746 The established common variant at *FOXSI* was not associated with BP in the conditional analysis, but new
747 rare variants in *FOXSI* (rs45499294, p.Glu74Lys; MAF = 0.0037) and *MYLK2* (rs149972827; MAF =
748 0.0036; Supplementary Information) were associated with BP. Two BP-associated SNVs (rs145502455,
749 p.Ile806Val; rs117874826, p.Glu564Ala) highlight *PLCB3* as a candidate gene. Phospholipase C is a key
750 enzyme in phosphoinositide metabolism, with *PLCB3* as the major isoform in macrophages⁴⁰, and a
751 negative regulator of VEGF-mediated vascular permeability, a key process in ischemic disease and cancer⁴¹.

752 PLCβ3 deficiency is associated with decreased atherogenesis, increased macrophage apoptosis in
753 atherosclerotic lesions, and increased sensitivity to apoptotic induction *in vitro*⁴⁰. Variants in *SOS2* have
754 previously been linked to kidney development/function⁴² and also cause Noonan syndromes 1 and 9, which
755 are rare inherited conditions characterized by craniofacial dysmorphic features and congenital heart defects,
756 including hypertrophic cardiomyopathy⁴³. Here we report the rare variant rs72681869 (p.Arg191Pro) in
757 *SOS2* as associated with SBP, DBP, PP, and HTN, highlighting *SOS2* as a candidate gene. Previously, we
758 identified a rare missense BP-associated variant in *RRAS*, a gene causing Noonan syndrome¹³. Our
759 discoveries of rare missense variants at known BP loci provide additional support for candidate genes at
760 these loci.

761 We report new low-frequency variant associations, such as the missense variant rs45573936 (T>C,
762 Ile216Thr) in *SLC29A1*. The minor allele is associated with both decreased SBP and DBP (Table 1), and the
763 SNV has been shown to affect the function of the encoded protein, equilibrative nucleoside transporter
764 (ENT1)⁴⁴. Best et al.⁴⁵ showed that loss of function of ENT1 caused an (~2.75-fold) increase in plasma
765 adenosine and (~15%) lower BP in mice. Drugs, including dipyridamole and S-(4-Nitrobenzyl)-6-
766 thioinosine (NBTI, NBMPR), are currently used as ENT1 inhibitors for their anti-cancer, anti-cardio, and
767 neuro-protective properties, and our results provide the genetic evidence to indicate that ENT1 inhibition
768 might lower BP in humans.

769 We found greater enrichment of SBP-associated SNVs in DHS hotspots in fetal vs. adult heart
770 muscle tissue. These results suggest that BP-associated SNVs may influence the expression of genes that are
771 critical for fetal development of the heart. This is consistent with our finding that some BP-associated genes
772 also cause congenital heart defects (see above). Furthermore, *de novo* mutations in genes with high
773 expression in the developing heart, as well as in genes that encode chromatin marks that regulate key
774 developmental genes, have previously been shown to be enriched in congenital heart disease patients^{46,47}. A
775 recent study of atrial fibrillation genetics, for which BP is a risk factor, described enrichment in DHS in fetal
776 heart⁴⁸. The authors hypothesized that the corresponding genes acting during fetal development increase risk
777 of atrial fibrillation⁴⁸. Together, these data suggest that early development and/or remodeling of cardiac
778 tissues may be an important driver of BP regulation later in life.

779 The BP measures we have investigated here are correlated; amongst the 107 new genetic BP loci,
780 only two are genome-wide significant across all four BP traits (*RP11-284M14.1* and *VTN*; Fig. 2). None of
781 the new loci were unique to HTN (Fig. 2), perhaps as HTN is derived from SBP and DBP, or perhaps due to
782 reduced statistical power for a binary trait. The results from our study indicate rare BP-associated variants
783 contribute to BP variability in the general population, and their identification has provided information on
784 new candidate genes and potential causal pathways. We have primarily focused on the exome array, which
785 is limited. Future studies using both exome and whole genome sequencing in population cohorts (e.g. UKBB
786 and TOPMed) will lead to identification of further rare variant associations and may advance the
787 identification of causal BP genes across the ~1,000 reported BP loci.

788

789 **CONSORTIA**

790

791 **LifeLines Cohort Study**

792 Rudolf A. de Boer¹⁸², Pim van der Harst^{240,241,242}, Peter van der Meer²⁴² and Niek Verweij²⁴⁴

793

794 **EPIC-CVD**

795 Adam S. Butterworth^{1,2,3,68,185} and John Danesh^{1,2,3,68,185,186}

796

797 **EPIC-InterAct**

798 Claudia Langenberg²⁰, Panos Deloukas^{9,21,50,184}, Mark I. McCarthy^{56,57,122}, Paul W. Franks^{70,190,191,192}, Olov
799 Rolandsson¹⁹¹ and Nicholas J. Wareham²⁰

800

801 **Understanding Society Scientific Group**

802 Bram P. Prins¹ and Eleftheria Zeggini^{245,246}

803

804 **Million Veterans Program**

805 Jacklyn N. Hellwege¹⁵, Ayush Giri^{15,16}, Digna R. Velez Edwards⁸⁷, Kelly Cho^{106,107,108}, J. Michael
806 Gaziano^{106,107,108}, Csaba P. Kovesdy¹²⁵, Yan V. Sun¹⁵⁰, Philip S. Tsao¹⁵⁴, Peter W. F. Wilson¹⁶⁴, Todd L.
807 Edwards²⁵⁰, Adriana M. Hung²⁵¹ and Christopher J. O'Donnell²⁵⁷

808

809 **ACKNOWLEDGEMENTS**

810 P. Surendran is supported by a Rutherford Fund Fellowship from the Medical Research Council grant
811 MR/S003746/1. N. Lahrouchi is supported by the Foundation “De Drie Lichten” in The Netherlands and the
812 Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation
813 (CVON2012-10 PREDICT and CVON2018-30 PREDICT2). J. N. Hellwege was supported by the
814 Vanderbilt Molecular and Genetic Epidemiology of Cancer (MAGEC) Training Program (T32CA160056,
815 PI X.-O. Shu). N. Franceschini is supported by the National Institute of Health awards HL140385,
816 MD012765 and DK117445. F. W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research
817 Centre. P. Deloukas’s work was supported by the British Heart Foundation (BHF) grant RG/14/5/30893. R.
818 J. F. Loos is funded by R01DK110113, U01HG007417, R01DK101855, R01DK107786. C. Hayward is
819 supported by an MRC University Unit Programme Grant MC_UU_00007/10 (QTL in Health and Disease)
820 and MRC University Unit Programme Grant MC_PC_U127592696. M. I. McCarthy* is a Wellcome Senior
821 Investigator (098381; 212259) and an NIHR Senior Investigator (NF-SI-0617-10090). The research was
822 supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC),
823 and by the Wellcome (090532, 106130, 098381, 203141, 212259). T. Ferreira* is supported by the NIHR
824 Biomedical Research Centre, Oxford. M. Tomaszewski is supported by British Heart Foundation
825 (PG/17/35/33001 and PG/19/16/34270) and Kidney Research UK (RP_017_20180302). J. Danesh* is funded
826 by the National Institute for Health Research (Senior Investigator Award). C. M. Lindgren* is supported by
827 the Li Ka Shing Foundation, WT-SSI/John Fell funds and by the NIHR Biomedical Research Centre,
828 Oxford, by Widenlife and NIH (5P50HD028138-27). J. M. M. Howson* was funded by the National
829 Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University
830 Hospitals NHS Foundation Trust).

831 *The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the
832 Department of Health and Social Care.

833 Full acknowledgements and full lists of consortia members are provided in the Supplementary Note.

834
835 **AUTHOR CONTRIBUTIONS**

836 These authors contributed to the drafting of the manuscript: P. Surendran, E.V.F., N.L., I.N., A.C.M.,
837 B.M.P., E.B., D.I.C., D.L., P.B.M., and J.M.M.H. The following authors were involved in the central
838 analyses: P. Surendran, E.V.F., N.L., I.N., S. Karthikeyan, J. Cook, D.J.L., F.D., C.N.-C., P.B.M., and
839 J.M.M.H. All authors critically reviewed and approved the final version of the manuscript. The following
840 authors performed bioinformatics analyses: S. Karthikeyan, L.C., B.M., C.Y., A.T.K., J.H.C., B.P.P., I.D.S.,
841 C.P.C., J.M.E., A.A., E.B.F., C.N.F., L.A.L., D.S.P., J.R.S., S. Burgess, M.K., J.P., E.Y., M.R.B., M.T.,
842 P.B.M., and J.M.M.H. Study Analysts: J.N.H., A.G., V.T., G. Thorleifsson, B.P.P., J.M.E., A.A., P.L.A.,
843 L.F.B., J.C.B., V.S.B., J.A.B., E.W.D., F.D., S.F.N., J.D.F., C.F., T.F., H.G., O.G., F.G., D.F.G., X.G.,
844 S.E.H., A.S.H., A.H., J.E.H., S.H., S. Kanoni, J.K., M.G.L., R.L., J. Lindström, Y.L., J. Luan, A.M., G.M.,
845 N.G.M., H.M., C.M., D.M., M. Müller-Nurasyid, G.P., M.P., A.P., R. Rainer, M. Richard, T.G.R., N.
846 Sepúlveda, X.S., A.V.S., J.A.S., A.S., P. Sulem, S. Thériault, U.T., S. Trompet, T.V.V., D.R.V.E., G.V.,
847 S.W., S.M.W., J.Y., R.Y., B.Y., W. Zhang, J.Z., W. Zhao (UPenn), W. Zhao (UMich), E.E., L.L.B., K.C.,
848 T.L., I.L., M.N., N.W.R., M. Reedik, T.S., I.T., H.R.W., H.Z., S.F., B.J.H., M.I.M., T.D.S., A.S.B., H.H., C.
849 Liu, A.K.M., A.P.M., A.C.M., D.I.C., and J.M.M.H. Study Principal Investigators (PI) or Co-PIs: N.F.,
850 D.O.M., I.B., P.S.B., C.C., J. Connell, A.F.D., J.M.G., N.G., T.H., F. Karpe, H.A.K., K.K., M. Moitry,
851 C.N.A.P., O. Pedersen, N.P., A.R., F.R., P. J. Sever, E. Tõnu, C.J.W., P. Almgren, P. Amouyel, F.W.A.,
852 A.I.B., M.B., M.L.B., E.P.B., J.E.B., J.C.C., Y.I.C., R.C., D.C., A.C., G.D.S., R.A.d.B., I.J.D., G.D., P.D.,
853 E.D.A., P.E., S.B.F., J.F., I.F., M.F., P.W.F., P.F., G.G., T.R.G., L.G., V.G., T.B.H., C.H., B.J.H., K.H., E.I.,
854 T.J., M.J., J.W.J., S.L.K., F. Kee, J.S.K., C.K., L.J.L., L. Lind, R.J.F.L., A.a.S.M., L.M., M.I.M., O.M.,
855 K.L.M., A.D.M., B.G.N., M.O., C.J.P., S.P., W.P., O. Polasek, D.J.P., A.M.P., M.A.P., C.L.R., K.R.,
856 P.M.R., O.R., F.R.R., J.I.R., I.R., V.S., N.J.S., N. Sattar, W.H.S., B.H.S., N. Soranzo, T.D.S., J.M.S., S.S.,
857 K.D.T., L.A.T., N.J.T., M.D.T., P.v.d.H., P.v.d.M., V.S.R., N.V., J.V., U.V., D.R. Weir, E.Z., F.J.C.,

858 N.J.W., C. Langenberg, M.T., A.S.B., M.J.C., J.D., T.L.E., A.M.H., C.M.L., A.P.M., C.O., B.M.P., D.S.,
859 K.S., E.B., D.I.C., D.L., P.B.M., and J.M.M.H. Study phenotyping: A.T.K., J.D.F., M.G.L., Y.L., S.A., E.A.,
860 S. Blankenberg, R.d.M., M.D., G.E., A.F., M.L.G.-G., G. Hallmans, G. Heiss, P.J., E.K., A.K., K.K., T.L.,
861 L. Lannfelt, W.L., L.W.M., M.N., G.J.P., K.L.R., M. Reedik, F.R., R. Rettig, J.R., P.J. Schreiner, E.L.S.,
862 J.S., G. Thorgeirsson, E. Trabetti, T.T., S.T.T., I.T., I.V., A.V., P. Amouyel, J.E.B., J.C.C., Y.I.C., R.A.d.B.,
863 J.F., G.G., V.G., B.J.H., F. Kee, J.S.K., L. Lind, R.J.F.L., O.M., W.P., O. Polasek, P.M.R., I.R., N. Sattar,
864 W.H.S., T.D.S., J.M.S., P.v.d.H., P.v.d.M., N.V., J.V., D.R. Weir, B.M.P., D.I.C., and D.L.

865

866 **COMPETING INTERESTS**

867 The following authors affiliated with deCODE genetics/Amgen Inc. are employed by the company: Vinicius
868 Tragante, Gudmar Thorleifsson, Anna Helgadóttir, Patrick Sulem, Gudmundur Thorgeirsson, Hilma Holm,
869 Daniel F. Gudbjartsson, Unnur Thorsteinsdóttir, Kari Stefansson. Bruce Psaty serves on the Steering
870 Committee of the Yale Open Data Access Project funded by Johnson & Johnson. John Danesh reports
871 grants, personal fees and non-financial support from Merck Sharp & Dohme (MSD), grants, personal fees
872 and non-financial support from Novartis, grants from Pfizer, and grants from AstraZeneca outside the
873 submitted work. Adam Butterworth reports grants outside of this work from AstraZeneca, Biogen, Merck,
874 Novartis, and Pfizer and personal fees from Novartis. Veikko Salomaa has participated in a conference trip
875 sponsored by Novo Nordisk and received an honorarium for participating in an advisor board meeting,
876 outside the present study. He also has ongoing research collaboration with Bayer Ltd, outside the present
877 study. Dennis Mook-Kanamori is a part-time clinical research consultant for Metabolon, Inc. Mark I.
878 McCarthy has served on advisory panels for Pfizer, Novo Nordisk, Zoe Global, has received honoraria from
879 Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer
880 Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As
881 of June 2019, he is an employee of Genentech, and a holder of Roche stock. Eric B. Fauman is an employee
882 of and owns stock in Pfizer, Inc. Mark J. Caulfield is Chief Scientist for Genomics England, a UK
883 Government company. Joanna M. M. Howson became a full-time employee of Novo Nordisk, and I.N.
884 became a full-time employee of Gilead during revision of the manuscript.

REFERENCES

1. Forouzanfar, M.H. *et al.* Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. *JAMA* **317**, 165-182 (2017).
2. Newton-Cheh, C. *et al.* Genome-wide association study identifies eight loci associated with blood pressure. *Nat. Genet.* **41**, 666-676 (2009).
3. Cho, Y.S. *et al.* A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. *Nat. Genet.* **41**, 527-534 (2009).
4. Levy, D. *et al.* Genome-wide association study of blood pressure and hypertension. *Nat. Genet.* **41**, 677-687 (2009).
5. Kato, N. *et al.* Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. *Nat. Genet.* **43**, 531-538 (2011).
6. Wain, L.V. *et al.* Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat. Genet.* **43**, 1005-1011 (2011).
7. International Consortium for Blood Pressure Genome-Wide Association Studies *et al.* Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* **478**, 103-109 (2011).
8. Johnson, A.D. *et al.* Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. *Hypertension* **57**, 903-910 (2011).
9. Johnson, T. *et al.* Blood pressure loci identified with a gene-centric array. *Am. J. Hum. Genet.* **89**, 688-700 (2011).
10. Tragante, V. *et al.* Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. *Am. J. Hum. Genet.* **94**, 349-360 (2014).
11. Simino, J. *et al.* Gene-age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, Global BPgen, and ICBP Consortia. *Am. J. Hum. Genet.* **95**, 24-38 (2014).
12. Kato, N. *et al.* Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. *Nat. Genet.* **47**, 1282-1293 (2015).
13. Surendran, P. *et al.* Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat. Genet.* **48**, 1151-1161 (2016).
14. Liu, C. *et al.* Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. *Nat. Genet.* **48**, 1162-1170 (2016).
15. Ehret, G.B. *et al.* The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. *Nat. Genet.* **48**, 1171-1184 (2016).
16. Hoffmann, T.J. *et al.* Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. *Nat. Genet.* **49**, 54-64 (2017).
17. Warren, H.R. *et al.* Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat. Genet.* **49**, 403-415 (2017).
18. Kraja, A.T. *et al.* New blood pressure-associated loci identified in meta-analyses of 475 000 individuals. *Circ. Cardiovasc. Genet.* **10**, e001778 (2017).
19. Wain, L.V. *et al.* Novel blood pressure locus and gene discovery using genome-wide association study and expression data sets from blood and the kidney. *Hypertension* (2017).
20. Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat. Genet.* **50**, 1412-1425 (2018).
21. Giri, A. *et al.* Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nat. Genet.* **51**, 51-62 (2019).
22. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76-82 (2011).
23. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209 (2018).

- 936 24. Loh, P.R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large
937 cohorts. *Nat. Genet.* **47**, 284-290 (2015).
- 938 25. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide
939 association studies. *Bioinformatics* **32**, 1493-1501 (2016).
- 940 26. Wu, M.C. *et al.* Rare-variant association testing for sequencing data with the sequence kernel
941 association test. *Am. J. Hum. Genet.* **89**, 82-93 (2011).
- 942 27. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
- 943 28. Marouli, E. *et al.* Rare and low-frequency coding variants alter human adult height. *Nature* **542**, 186-
944 190 (2017).
- 945 29. Liu, D.J. *et al.* Exome-wide association study of plasma lipids in > 300,000 individuals. *Nat. Genet.*
946 **49**, 1758-1766 (2017).
- 947 30. Finan, C. *et al.* The druggable genome and support for target identification and validation in drug
948 development. *Sci. Transl. Med.* **9**, eaag1166 (2017).
- 949 31. Foley, C.N. *et al.* A fast and efficient colocalization algorithm for identifying shared genetic risk
950 factors across multiple traits. *bioRxiv*, 592238 (2019).
- 951 32. Solovieff, N., Cotsapas, C., Lee, P.H., Purcell, S.M. & Smoller, J.W. Pleiotropy in complex traits:
952 challenges and strategies. *Nat. Rev. Genet.* **14**, 483-495 (2013).
- 953 33. Xu, X. *et al.* Molecular insights into genome-wide association studies of chronic kidney disease-
954 defining traits. *Nat. Commun.* **9**, 4800 (2018).
- 955 34. Rowland, J. *et al.* Uncovering genetic mechanisms of kidney aging through transcriptomics,
956 genomics, and epigenomics. *Kidney Int.* **95**, 624-635 (2019).
- 957 35. Staley, J.R. *et al.* PhenoScanner: a database of human genotype-phenotype associations.
958 *Bioinformatics* **32**, 3207-3209 (2016).
- 959 36. Turcot, V. *et al.* Protein-altering variants associated with body mass index implicate pathways that
960 control energy intake and expenditure in obesity. *Nat. Genet.* **50**, 26-41 (2018).
- 961 37. Vishram, J.K. *et al.* Impact of age on the importance of systolic and diastolic blood pressures for
962 stroke risk: the MONica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project.
963 *Hypertension* **60**, 1117-1123 (2012).
- 964 38. Messaoudi, S. *et al.* Endothelial Gata5 transcription factor regulates blood pressure. *Nat. Commun.* **6**,
965 8835 (2015).
- 966 39. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic
967 variants. *Nat. Genet.* **46**, 310-315 (2014).
- 968 40. Wang, Z. *et al.* Phospholipase C beta3 deficiency leads to macrophage hypersensitivity to apoptotic
969 induction and reduction of atherosclerosis in mice. *J. Clin. Invest.* **118**, 195-204 (2008).
- 970 41. Hoepfner, L.H. *et al.* Revealing the role of phospholipase Cbeta3 in the regulation of VEGF-induced
971 vascular permeability. *Blood* **120**, 2167-2173 (2012).
- 972 42. Li, M. *et al.* SOS2 and ACP1 loci identified through large-scale exome chip analysis regulate kidney
973 development and function. *J. Am. Soc. Nephrol.* **28**, 981-994 (2017).
- 974 43. Tidyman, W.E. & Rauen, K.A. Pathogenetics of the RASopathies. *Hum. Mol. Genet.* **25**, R123-R132
975 (2016).
- 976 44. Kim, J.H. *et al.* Functional role of the polymorphic 647 T/C variant of ENT1 (SLC29A1) and its
977 association with alcohol withdrawal seizures. *PLoS One* **6**, e16331 (2011).
- 978 45. Best, K.A., Bone, D.B., Vilas, G., Gros, R. & Hammond, J.R. Changes in aortic reactivity associated
979 with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice. *PLoS One* **13**, e0207198
980 (2018).
- 981 46. Zaidi, S. *et al.* De novo mutations in histone-modifying genes in congenital heart disease. *Nature*
982 **498**, 220-223 (2013).
- 983 47. Jin, S.C. *et al.* Contribution of rare inherited and de novo variants in 2,871 congenital heart disease
984 probands. *Nat. Genet.* **49**, 1593-1601 (2017).
- 985 48. Nielsen, J.B. *et al.* Genome-wide study of atrial fibrillation identifies seven risk loci and highlights
986 biological pathways and regulatory elements involved in cardiac development. *Am. J. Hum. Genet.*
987 **102**, 103-115 (2018).
- 988
- 989

991 **FIGURE LEGENDS**

992 **Figure 1 | Study design for single variant discovery. a**, Exome array-wide association study
993 (EAWAS) of SBP, DBP, PP and HTN. In Stage 1, we performed two fixed effect meta-analyses for
994 each of the blood pressure (BP) phenotypes SBP, DBP, PP and HTN: one meta-analysis including
995 810,865 individuals of European (EUR) ancestry and a second pan-ancestry (PA) meta-analysis
996 including 870,217 individuals of EUR, South Asians (SAS), East Asians (EAS), African Ancestry
997 (AA), Hispanics (HIS) and Native Americans (NAM) (Supplementary Tables 23 and 24; Methods).
998 Summary association statistics for SNVs with $P < 5 \times 10^{-8}$ in Stage 1 that were outside of previously
999 reported BP loci (Methods, Supplementary Tables 1 and 25) were requested in independent studies
1000 (up to 448,667 participants; Supplementary Table 24). In Stage 2, we performed both a EUR and a
1001 PA meta-analyses for each trait of Stage 1 results and summary statistics from the additional studies.
1002 Only SNVs that were associated with a BP trait at $P < 5 \times 10^{-8}$ in the combined Stage 2 EUR or PA
1003 meta-analyses and had concordant directions of effect across studies ($P_{\text{heterogeneity}} > 1 \times 10^{-4}$; Methods)
1004 were considered significant. Further details are provided in the Methods and Supplementary
1005 Information. **b**, Rare variant GWAS (RV-GWAS) of SBP, DBP and PP. For SNVs outside of the
1006 previously reported BP loci (Methods, Supplementary Tables 1 and 6) with $P < 1 \times 10^{-7}$ in Stage 1,
1007 summary association statistics were requested from MVP (up to 225,112 participants; Supplementary
1008 Table 24). In Stage 2, we performed meta-analyses of Stage 1 and MVP for SBP, DBP and PP in
1009 EUR. SNVs that were associated with a BP trait at $P < 5 \times 10^{-8}$ in the combined Stage 2 EUR with
1010 concordant directions of effect across UKBB and MVP ($P_{\text{heterogeneity}} > 1 \times 10^{-4}$; Methods) were
1011 considered significant. Justification of the significance thresholds used and further information on
1012 the statistical methods are detailed in the Methods and Supplementary Information. *Total number of
1013 participants analyzed within each study that provided single variant association summaries following
1014 the data request—EAWAS EUR: Million Veterans Program (MVP: 225,113), deCODE (127,478)
1015 and GENOA (1,505); EAWAS PA: Million Veterans Program (MVP: 225,113 EUR; 63,490 AA;
1016 22,802 HIS; 2,695 Nam; 4,792 EAS), deCODE (127,478 participants from Iceland) and GENOA
1017 (1,505 EUR; 792 AA); RV-GWAS EUR: Million Veterans Program (MVP: 225,112 EUR).

1018

1019 **Figure 2 | New BP associations. a**, Fuji plot of the genome-wide significant BP-associated SNVs
1020 from the Stage 2 EAWAS and Stage 2 rare variant GWAS. The first four circles (from inside-out)
1021 and the last circle (locus annotation) summarize pleiotropic effects, while circles 5 to 8 summarize
1022 the genome-wide significant associations. Every dot or square represents a BP-associated locus, and
1023 large dots represent novel BP-associated loci, while small dots represent loci containing novel

1024 variants identified in this study, which are in linkage disequilibrium with a variant reported by
1025 Evangelou et al.²⁰ and/or Giri et al.²¹. All loci are independent of each other, but due to the scale of
1026 the plot, dots for loci in close proximity overlap. *Loci with rare variant associations. **b**, Venn
1027 diagram showing the overlap of the 107 new BP loci across the analyzed BP traits. **c**, Functional
1028 annotation from VEP of all the identified rare variants in known and novel regions. **d**, Plots of minor
1029 allele frequency against effect estimate on the transformed scale for the BP-associated SNVs. Blue
1030 squares are new BP-associated SNVs, black dots represent SNVs at known loci, and red dots are
1031 newly identified distinct BP-associated SNVs at known loci. Effect estimates and SEs for the novel
1032 loci are taken from the Stage 2 EUR analyses (up to 1,164,961 participants), while for the known are
1033 from the Stage 1 analyses (up to 810,865 participants). Results are from the EAWAS where available
1034 and the GWAS (up to 670,472 participants) if the known variants were not on the exome array (data
1035 from Supplementary Tables 1, 3, 7, 8, and 25 were used).

1036

1037 **Figure 3 | Annotation of BP loci.** **a**, BP associations shared with eQTL from GTEx through multi-
1038 trait colocalization analyses. Expressed gene and the colocalized SNV are provided on the y-axis. BP
1039 trait and eQTL tissues are provided on the x-axis. The color indicates whether the candidate SNV
1040 increases BP and gene expression (brown), decreases BP and gene expression (orange), or has the
1041 inverse effects on BP and gene expression (blue). **b**, Enrichment of BP-associated SNVs in DNase I
1042 hypersensitivity hot spots (active chromatin). The top plot is for SBP, middle is for DBP, and bottom
1043 represents PP. Height of the bar indicates the fold enrichment in the listed tissues, with error bars
1044 representing the 95% confidence intervals. The colors represent the enrichment *P*-value.

1045

1046 **Figure 4 | Phenome-wide associations of the new BP loci.** **a**, Modified Fuji plot of the genome-
1047 wide significant associated SNVs from the Stage 2 EAWAS and Stage 2 rare variant GWAS (novel
1048 loci only). Each dot represents a novel locus where a conditionally independent variant or a variant in
1049 LD with the conditionally independent variant has been previously associated with one or more traits
1050 unrelated to blood pressure, and each circle represents different trait category (Supplementary Table
1051 20). Locus annotation is plotted in the outer circle, and * sign denotes loci where the conditionally
1052 independent signal maps to a gene which is different to the one closest to the sentinel variant. **b**, Bar
1053 chart showing the distribution of traits (x-axis) and number of distinct BP-associated variants per trait
1054 (y-axis) that the SNVs in **a** are associated with. **c**, Bar chart of the number of traits included in **b** (y-
1055 axis) by trait category (x-axis). The color coding for **a** and **b** is relative to **c**.

1056

1057 **Figure 5 | Causal association of BP with stroke and coronary artery disease.** Mendelian
1058 randomization analyses of the effect of blood pressure on stroke and coronary artery disease. **a**,
1059 Univariable analyses. **b**, Multivariable analyses (Methods). Analyses were performed using summary
1060 association statistics (Methods). The causal estimates are on the odds ratio (OR) scale (the square in
1061 the plot). The whiskers on the plots are the 95% confidence intervals for these ORs. Results on the
1062 standard deviation scale are provided in Supplementary Table 22. The genetic variants for the
1063 estimation of the causal effects in this plot are sets of SNVs after removing the confounding SNVs
1064 and invalid instrumental variant. OR, odds ratio (*P*-value from the inverse variance weighted two
1065 sample Mendelian randomization method). *n*, number of disease cases.

1066
1067
1068
1069
1070

Table 1 | Rare and low-frequency SNV-blood pressure associations in participants of European ancestry from the (Stage 2) EAWAS and (Stage 2) RV-GWAS that map to new BP loci

Locus	rsID	Chr.Pos	Gene	EA/OA	Amino acids	Consequence	Trait	EAF	β	P	Het P	n
Exome array-wide association study (EAWAS)												
10	rs11580946	1:150,551,327	<i>MCL1</i>	A/G	p.Val227Ala	missense	PP	0.016	-0.37	2.74x10 ⁻⁹	0.24	1,159,900
11	rs61747728†	1:179,526,214	<i>NPHS2</i>	T/C	p.Gln229Arg	missense	DBP	0.040	0.26	8.74x10 ⁻¹³	0.22	1,160,530
16	rs4149909	1:242,023,898	<i>EXO1</i>	G/A	p.Ser279Asn	missense	SBP	0.033	0.36	2.46x10 ⁻⁸	0.09	1,158,190
32	rs3821033†	2:219,507,302	<i>ZNF142</i>	T/C	p.Thr1313Ala	missense	DBP	0.033	-0.29	1.42x10 ⁻¹³	0.75	1,160,530
	rs16859180†	2:219,553,468	<i>STK36</i>	T/C	p.Trp477Arg	missense	DBP	0.049	-0.26	1.11x10 ⁻¹⁶	0.34	1,160,530
44	rs145072852	3:101,476,645	<i>CEP97</i>	T/C	p.Phe399Leu	missense	PP	0.004	1.05	1.42x10 ⁻¹³	0.01	1,158,820
46	rs139600783	3:119,109,769	<i>ARHGAP31</i>	T/C	p.Ser274Pro	missense	HTN	0.008	5.85	5.05x10 ⁻⁹	0.19	975,381
50	rs73181210	3:169,831,268	<i>PHC3</i>	C/T	p.Glu692Lys	missense	DBP	0.009	-0.66	9.14x10 ⁻¹⁵	0.04	1,159,580
52	rs11937432†	4: 2,233,709	<i>HAUS3</i>	G/A	p.Thr586Ile	missense	DBP	0.046	0.21	9.56x10 ⁻¹⁰	0.26	1,160,520
58	rs1229984	4:100,239,319	<i>ADH1B</i>	T/C	p.His48Arg	missense	PP	0.026	-0.75	2.97x10 ⁻²⁵	0.54	686,104
63	rs143057152	4:149,075,755	<i>NR3C2</i>	T/C	p.His771Arg	missense	SBP	0.003	1.75	4.14x10 ⁻¹⁴	0.22	1,128,880
71	rs61755724	5:132,408,967	<i>HSPA4</i>	A/G	p.Thr159Ala	missense	DBP	0.024	0.26	9.75x10 ⁻⁹	0.36	1,160,530
72	rs33956817	5:137,278,682	<i>FAM13B</i>	C/T	p.Met802Val	missense	SBP	0.044	0.31	1.76x10 ⁻⁸	0.27	1,158,190
77	rs34471628†	5:172,196,752	<i>DUSP1</i>	G/A	p.His187Tyr	missense	DBP	0.039	-0.23	3.00x10 ⁻¹⁰	0.42	1,153,300
85	rs45573936	6: 44,198,362	<i>SLC29A1</i>	C/T	p.Ile295Thr	missense	DBP	0.027	-0.38	3.70x10 ⁻¹⁹	0.59	1,160,530
100	rs144867634	7:111,580,166	<i>DOCK4</i>	C/T	p.Val326Met	missense/splice region	DBP	0.025	-0.26	2.62x10 ⁻⁸	0.04	1,160,530
109	rs56335308†	8: 17,419,461	<i>SLC7A2</i>	A/G	p.Met545Val	missense	DBP	0.025	0.31	1.40x10 ⁻¹⁰	0.26	1,160,530
114	rs76767219	8: 81,426,196	<i>ZBTB10</i>	A/C	p.Glu346Ala	missense	SBP	0.034	-0.44	4.41x10 ⁻¹³	0.18	1,160,830
119	rs61732533†	8:145,108,151	<i>OPLAH</i>	A/G	-	synonymous	DBP	0.049	-0.21	2.05x10 ⁻¹⁰	0.86	1,085,170
	rs34674752†	8:145,154,222	<i>SHARPIN</i>	A/G	p.Ser294Pro	missense	DBP	0.049	-0.19	5.89x10 ⁻¹⁰	0.91	1,132,350
146	rs117874826	11: 64,027,666	<i>PLCB3</i>	C/A	p.Ala564Glu	missense	SBP	0.014	0.71	4.67x10 ⁻¹²	0.42	1,153,360
	rs145502455	11: 64,031,030	<i>PLCB3</i>	A/G	p.Ile806Val	missense	SBP	0.005	0.90	5.01x10 ⁻⁹	0.04	1,156,310
154	rs141325069	12: 20,769,270	<i>PDE3A</i>	A/G	p.Gln459Arg	missense	SBP	0.003	1.45	6.25x10 ⁻¹¹	0.82	1,134,260
158	rs77357563	12:114,837,349	<i>TBX5</i>	A/C	p.Tyr111Asp	missense	PP	0.005	-1.01	7.72x10 ⁻²²	0.22	1,152,080
159	rs13141	12:121,756,084	<i>ANAPC5</i>	A/G	p.Val630Ala	missense	DBP	0.011	0.52	1.98x10 ⁻¹²	0.63	1,156,950

168	rs17880989†	14: 23,313,633	<i>MMP14</i>	A/G	p.Ile355Met	missense	DBP	0.027	0.32	2.02x10 ⁻¹⁴	0.95	1,160,530
169	rs61754158	14: 31,774,324	<i>HEATR5A</i>	T/C	p.Arg1670Gly	missense	SBP	0.009	-0.70	6.28x10⁻⁹	0.04	1,119,230
170	rs72681869	14: 50,655,357	<i>SOS2</i>	C/G	p.Arg191Pro	missense	SBP	0.010	-1.22	2.25x10⁻²²	0.25	1,144,040
177	rs150843673	15: 81,624,929	<i>TMC3</i>	T/G	p.Ser1045Ter	stop/lost	DBP	0.021	0.36	1.43x10 ⁻¹²	0.14	1,154,000
181	rs61739285	16: 27,480,797	<i>GTF3C1</i>	T/C	p.His1630Arg	missense	DBP	0.035	0.24	4.71x10 ⁻¹⁰	0.04	1,155,020
186	rs62051555	16: 72,830,539	<i>ZFH3</i>	G/C	p.His2014Gln	missense	PP	0.048	0.47	1.19x10 ⁻²⁵	0.43	797,332
206	rs11699758	20: 60,901,762	<i>LAMA5</i>	T/C	p.Ile1757Val	missense	PP	0.034	-0.26	6.68x10 ⁻¹¹	0.54	1,154,410
	rs13039398	20: 60,902,402	<i>LAMA5</i>	A/G	p.Trp1667Arg	missense	PP	0.033	-0.26	1.89x10 ⁻¹⁰	0.44	1,133,830

Rare variant – genome-wide association study (RV-GWAS)

215	rs55833332	1:198,222,215	<i>NEK7</i>	G/C	p.Gly35Arg	missense	PP	0.008	0.62	4.58x10⁻⁸	0.08	670,129
	rs143554274	1:198,455,391	<i>ATP6V1G3</i>	T/C	-	intergenic	PP	0.008	0.71	1.26x10 ⁻⁹	0.14	670,128
216	rs12135454	1:219,310,461	<i>LYPLAL1-AS1</i>	T/C	-	intron	PP	0.010	-0.62	1.61x10 ⁻⁸	0.22	665,523
	rs12128471	1:219,534,485	<i>RP11-392O17.1</i>	A/G	-	intergenic	PP	0.010	-0.68	2.99x10 ⁻⁹	0.19	670,130
217	rs114026228	4: 99,567,918	<i>TSPAN5</i>	C/T	-	intron	PP	0.008	-0.65	5.20x10 ⁻⁹	0.03	670,128
	rs145441283	4: 99,751,794	<i>EIF4E</i>	G/A	-	intergenic	PP	0.010	-0.71	2.01x10 ⁻¹¹	0.08	670,128
219	rs187207161	6:122,339,304	<i>HMGB3P18</i>	C/T	-	intergenic	PP	0.009	-0.63	2.16x10 ⁻¹⁰	0.02	670,130
221	rs149165710	8:121,002,676	<i>DEPTOR</i>	A/G	-	intron	PP	0.003	1.32	2.78x10 ⁻¹²	0.03	665,523
222	rs184289122	10:106,191,229	<i>CFAP58</i>	G/A	-	intron	SBP	0.008	1.31	1.66x10 ⁻¹³	0.53	670,472
	rs7076147	10:106,250,394	<i>RP11-127O4.3</i>	G/A	-	intergenic	SBP	0.010	1.11	1.71x10 ⁻¹⁴	0.75	670,472
	rs75337836	10:106,272,188	<i>RP11-127O4.3</i>	T/G	-	intergenic	SBP	0.010	1.12	2.67x10 ⁻¹⁵	0.54	670,472
	rs142760284	10:106,272,601	<i>RP11-127O4.3</i>	A/C	-	intergenic	SBP	0.009	1.22	2.19x10 ⁻¹⁵	0.92	670,472
	rs576629818	10:106,291,923	<i>RP11-127O4.3</i>	T/C	-	intergenic	SBP	0.009	1.24	1.02x10 ⁻¹⁵	0.71	670,472
	rs556058784	10:106,322,283	<i>RP11-127O4.2</i>	G/A	-	intergenic	SBP	0.009	1.26	4.54x10 ⁻¹⁶	0.57	665,861
	rs535313355†	10:106,399,140	<i>SORCS3</i>	C/T	-	upstream gene	SBP	0.009	1.36	1.04x10 ⁻¹⁷	0.22	670,472
	rs181200083†	10:106,520,975	<i>SORCS3</i>	C/A	-	intron	SBP	0.009	1.60	1.08x10 ⁻²¹	0.58	665,861
	rs540369678†	10:106,805,351	<i>SORCS3</i>	T/A	-	intron	SBP	0.010	1.18	2.29x10 ⁻¹⁴	0.16	670,472
	rs117627418	10:107,370,555	<i>RP11-45P22.2</i>	T/C	-	intergenic	SBP	0.009	1.11	1.98x10 ⁻¹¹	0.1	665,861
224	rs138656258	14: 31,541,910	<i>AP4S1</i>	G/T	-	intron	SBP	0.007	-0.93	1.15x10 ⁻⁸	0.13	665,861
228	rs6061911	20: 60,508,289	<i>CDH4</i>	C/T	-	intron	SBP	0.010	-0.85	4.67x10 ⁻⁸	0.09	665,861
	rs114580352	20: 60,529,963	<i>TAF4</i>	A/G	-	intron	SBP	0.009	-0.84	1.99x10 ⁻⁸	0.04	665,860

rs11907239	20: 60,531,853	TAF4	A/G	-	intron	SBP	0.009	-0.82	4.99x10 ⁻⁸	0.05	670,472
rs200383755	20: 61,050,522	GATA5	C/G	p.Trp19Ser	missense	DBP	0.006	1.00	1.01x10⁻¹³	0.49	670,172

Newly identified rare and low-frequency SNV-inverse normal transformed blood pressure associations are reported from Stage 2 of the exome array study and genome-wide association study. The reported associations are for the trait with the smallest *P*-value in the Stage 1 meta-analysis; the full results are provided in Supplementary Tables 2 and 7. SNVs are ordered by trait, chromosome, and position. Gene, gene containing the SNV or the nearest gene; rsID, dbSNP rsID; Chr:Pos, Chromosome:NCBI Build 37 position; EA/OA, effect allele (also the minor allele) and other allele; EAF, effect allele frequency based on Stage 1; Consequence, consequence of the SNV to the transcript as annotated by VEP; Amino acids, reference and variant amino acids from VEP; Trait, blood pressure trait for which association is reported; β , effect estimate, in mmHg, from the Stage 2 meta-analysis of the *untransformed* BP trait or the *Z*-score from the HTN analyses in Stage 2; *P*, *P*-value for association with the listed inverse normal transformed blood pressure trait from the Stage 2 meta-analyses; Het_*P*, *P*-value for heterogeneity; *n*, sample size. Bold type indicates rare missense variants.

†Novel variants identified in this study that are in linkage disequilibrium (LD: $r^2 > 0.6$ rare SNVs and $r^2 > 0.1$ common SNVs) with a variant that has been reported by Evangelou et al.²⁰ and/or Giri et al.²¹ within +/- 500 kb of the novel variant.

Table 2 | Conditionally independent rare and very low-frequency SNV (MAF < 0.02) associations from exome array at known loci in Stage 1 EUR studies

Locus ID	rsID	Chr:bp	Gene	EA/OA	AA	Consequence	Trait	EAF	β_{joint}	P_{joint}	<i>n</i>	Ref
18	rs116245325	1: 153665650	<i>NPR1</i> *	T/C	p.Phe1034Leu	Missense	SBP	0.001	0.1660	7.49x10 ⁻⁹	758,252	14
	rs61757359	1: 153658297		A/G	p.Ser541Gly	Missense		0.003	-0.0812	6.10x10 ⁻⁹	794,698	
	rs35479618 **	1: 153662423		A/G	p.Lys967Glu	Missense		0.017	0.0694	1.19x10 ⁻²⁸	774,862	
28	rs1805090	1: 230840034	<i>AGT</i> *	T/G	p.Met392Leu	Missense	DBP	0.002	0.1070	6.00x10 ⁻¹⁰	759,349	8
	rs699	1: 230845794		G/A	p.Thr268Met	Missense	DBP	0.408	0.0225	2.12x10 ⁻⁴⁵	806,731	
94	rs111620813	4: 8293193	<i>HTRA3</i> *	A/G	p.Met269Val	Missense	PP	0.011	-0.0432	1.38x10 ⁻⁸	798,063	18
	rs7437940 **	4: 7887500	<i>AFAP1</i>	T/C	-	Intron	PP	0.406	-0.0131	1.62x10 ⁻¹⁶	806,708	
102	rs112519623	4: 103184239	<i>SLC39A8</i> *	A/G	p.Phe449Leu	Missense	DBP	0.016	-0.0391	3.02x10 ⁻¹⁰	803,151	6
	rs13107325 **	4: 103188709		T/C	p.Thr391Ala	Missense	DBP	0.072	-0.0615	9.69x10 ⁻⁸⁸	806,731	
	rs4699052	4: 104137790	<i>CENPE</i>	T/C	-	Intergenic	DBP	0.388	-0.0121	7.31x10 ⁻¹⁴	806,731	
105	rs6825911	4: 111381638	<i>ENPEP</i>	T/C	-	Intron	DBP	0.205	-0.0215	1.47x10 ⁻²⁸	801,965	
	rs33966350	4: 111431444		A/G	p.Ter413Trp	Stop/lost	DBP	0.013	0.0735	2.40x10 ⁻²⁵	798,385	
144	rs4712056 **	6: 53989526	<i>MLIP</i>	G/A	p.Val159Ile	Missense	PP	0.360	0.0091	1.86x10 ⁻⁸	806,708	14,16,13
	rs115079907	6: 55924005	<i>COL21A1</i> *	T/C	p.Arg882Gly	Missense	PP	0.003	0.2060	8.33x10 ⁻¹⁷	783,546	
	rs12209452	6: 55924962		G/A	p.Pro821Leu	Missense	PP	0.049	0.0411	5.49x10 ⁻²⁶	743,036	
	rs200999181 **	6: 55935568		A/C	p.Val665Gly	Missense	PP	0.001	0.3350	4.74x10 ⁻⁴³	764,864	
	rs35471617	6: 56033094		A/G	p.Met343Thr	Missense/splice region	PP	0.073	0.0249	1.03x10 ⁻¹⁵	806,708	
208	rs2764043	6: 56035643		G/A	p.Pro277Leu	Missense	PP	0.002	0.1530	5.11x10 ⁻¹⁴	785,643	
	rs1925153 **	6: 56102780		T/C	-	Intron	PP	0.448	-0.0096	1.03x10 ⁻⁸	786,734	
	rs4294007	6: 57512510	<i>PRIM2</i>	T/G	-	Splice acceptor	PP	0.379	0.0096	1.13x10 ⁻⁷	632,625	
	rs507666	9:136149399	<i>ABO</i>	A/G	-	Intron	DBP	0.189	-0.0293	7.53x10 ⁻⁴⁷	796,103	13,15
	rs3025343	9:136478355	<i>LL09NC01-254D11.1</i>	A/G	-	Exon (noncoding transcript)	DBP	0.112	-0.0126	4.91x10 ⁻⁷	806,731	
223	rs77273740	9:136501728	<i>DBH</i>	T/C	p.Trp65Arg	Missense	DBP	0.027	-0.0846	3.85x10 ⁻¹¹	790,500	
	rs3025380	9:136501756	<i>DBH</i>	C/G	p.Ala74Gly	Missense	DBP	0.005	-0.1030	5.37x10 ⁻¹⁸	795,263	
	rs74853476	9:136501834	<i>DBH</i>	T/C	-	Splice donor	DBP	0.002	0.1000	3.69x10 ⁻⁸	775,793	
	rs201422605	10: 95993887	<i>PLCE1</i>	G/A	p.Val678Met	Missense	SBP	0.003	-0.0837	1.41x10 ⁻⁷	795,009	7,14
	rs11187837	10: 96035980		C/T	-	Intron	SBP	0.110	-0.0198	4.23x10 ⁻¹⁴	801,969	
229	rs17417407	10: 95931087		T/G	p.Leu548Arg	Missense	SBP	0.167	-0.0122	9.97x10 ⁻⁹	806,735	
	rs9419788	10: 96013705		G/A	-	Intron	SBP	0.387	0.0137	9.63x10 ⁻¹⁶	806,735	
	rs60889456	11: 723311	<i>EPS8L2</i> *	T/C	p.Leu471Pro	Missense	PP	0.017	0.0303	6.37x10 ⁻⁷	799,021	17
246*	rs7126805 **	11: 828916	<i>CRACR2B</i>	G/A	p.Gln77Arg	Missense	PP	0.271	-0.0134	1.43x10 ⁻¹³	752,026	
246*	rs56061986	11: 89182686	<i>NOX4</i> *	C/T	p.Gly67Ser	Missense	PP	0.003	-0.1080	2.25x10 ⁻¹¹	798,273	17 16

	rs139341533	11: 89182666		A/C	p.Phe97Leu	Missense	PP	0.004	-0.0947	6.82x10⁻¹⁴	785,947	
	rs10765211	11: 89228425		A/G	-	Intron	PP	0.342	-0.0176	8.77x10 ⁻²⁷	806,708	
250	rs117249984	11: 107375422	<i>ALKBH8</i>	A/C	p.Tyr653Asp	Missense	SBP	0.019	-0.0304	2.90x10⁻⁷	805,695	16
	rs3758911	11: 107197640	<i>CWF19L2</i>	C/T	p.Cys894Tyr	Missense	SBP	0.341	0.0113	1.54x10 ⁻¹¹	806,735	
304	rs61738491	16: 30958481	<i>FBXL19</i> ⁺	A/G	p.Gln652Arg	Missense	PP	0.010	-0.0460	1.25x10⁻⁸	796,459	17,16
	rs35675346 ^{**}	16: 30936081		A/G	p.Lys10Glu	Missense	PP	0.241	-0.0125	1.06x10 ⁻¹¹	802,932	
130 [*]	rs114280473	5: 122714092	<i>CEP120</i> ⁺	A/G	p.Phe712Leu	Missense	PP	0.006	-0.0584	9.98x10⁻⁸	805,632	13, 12, 14, 15
	rs2303720	5: 122682334		T/C	p.His947Arg	Missense	PP	0.029	-0.0419	3.44x10 ⁻¹⁸	806,708	
	rs1644318	5: 122471989	<i>PRDM6</i>	C/T	-	Intron	PP	0.387	0.0192	2.43x10 ⁻³²	790,025	
179 [*]	rs3735080	7: 150217309	<i>GIMAP7</i>	T/C	p.Cys83Arg	Missense	DBP	0.237	-0.0092	6.56x10 ⁻⁷	806,731	9, 14, 10
	rs3807375	7: 150667210	<i>KCNH2</i>	T/C	-	Intron	DBP	0.364	-0.0084	3.94x10 ⁻⁷	806,731	
	rs3918234	7: 150708035	<i>NOS3</i> ⁺	T/A	p.Leu982Gln	Missense	DBP	0.004	-0.0727	1.33x10⁻⁷	786,541	
	rs891511 ^{**}	7: 150704843		A/G	-	Intron	DBP	0.331	-0.0231	1.56x10 ⁻⁴⁰	778,271	
	rs10224002 ^{**}	7: 151415041	<i>PRKAG2</i>	G/A	-	Intron	DBP	0.286	0.0186	7.41x10 ⁻²⁷	806,731	
190 [*]	rs138582164	8: 95264265	<i>GEM</i> ⁺	A/G	p.Ter199Arg	Stop lost	PP	0.001	0.2810	1.90x10⁻¹⁷	735,507	16, 78
195 [*]	rs112892337	8: 135614553	<i>ZFAT</i> ⁺	C/G	p.Cys470Ser	Missense	SBP	0.005	-0.0831	4.39x10⁻¹²	792,203	17
	rs12680655	8: 135637337		G/C	-	Intron	SBP	0.398	0.0118	1.81x10 ⁻¹³	797,982	
259 [*]	rs145878042	12: 48143315	<i>RAPGEF3</i> ⁺	G/A	p.Pro258Leu	Missense	SBP	0.012	-0.0453	9.28x10⁻¹⁰	805,791	16, 13
	rs148755202	12: 48191247	<i>HDAC7</i>	T/C	p.His166Arg	Missense	SBP	0.016	0.0310	9.07x10⁻⁷	806,735	
	rs1471997	12: 48723595	<i>H1FNT</i>	A/G	p.Gln174Arg	Missense	SBP	0.216	0.0130	1.15x10 ⁻¹¹	806,735	
	rs1126930 ^{**}	12: 49399132	<i>PRKAG1</i>	C/G	p.Ser98Thr	Missense	SBP	0.035	0.0408	1.45x10 ⁻²¹	793,216	
	rs52824916 ^{**}	12: 49993678	<i>FAM186B</i>	T/C	p.Gln582Arg	Missense	SBP	0.088	-0.0155	1.70x10 ⁻⁸	806,735	
	rs7302981 ^{**}	12: 50537815	<i>CERS5</i>	A/G	p.Cys75Arg	Missense	SBP	0.375	0.0219	1.52x10 ⁻⁴¹	806,735	
312 [*]	rs61753655	17: 1372839	<i>MYO1C</i> ⁺	T/C	p.Lys866Glu	Missense	SBP	0.011	0.0653	6.48x10⁻¹⁸	806,735	17, 16
	rs1885987	17: 2203025	<i>SMG6</i>	G/T	p.Thr341Asn	Missense	SBP	0.371	-0.0127	3.94x10 ⁻¹⁵	806,735	
339 [*]	rs34093919	19: 41117300	<i>LTBP4</i> ⁺	A/G	p.Asn715Asp	Missense/splice region	PP	0.014	-0.0631	4.18x10⁻²⁰	805,764	19
	rs814501	19: 41038574	<i>SPTBN4</i>	G/A	p.Gly1331Ser	Missense	PP	0.482	-0.0115	2.40x10 ⁻¹³	806,708	
346	rs45499294	20: 30433126	<i>FOXS1</i> ⁺	T/C	p.Lys74Glu	Missense	SBP	0.004	-0.0732	2.36x10⁻⁸	801,284	16

GCTA was used to perform conditional analyses of the meta-analysis results from the exome array study from the Stage 1 meta-analysis of EUR studies in known blood pressure regions (defined in Supplementary Table 1). All SNVs had $P < 0.0001$ for heterogeneity. The trait selected in this table is the trait for which the rare variant had the smallest P -value. We provide all conditionally independent variants at these loci, i.e. rare, very low frequency (MAF < 0.02), low frequency, and common. The full detailed listing of results is provided in Supplementary Table 8. Bold font highlights variants with MAF < 0.02. Locus ID, the known locus identifier used in Supplementary Table 1; Chr:Position,

chromosome and NCBI Build 37 physical position; EA/OA, Effect allele/other allele; AA, amino acid change; Effect, predicted consequence of the SNV from VEP; EAF, effect allele frequency; β_{joint} , effect estimate for the SNV in the joint analysis from GCTA; P_{joint} , the P -value for association of the rare variant from the joint analysis in GCTA; Gene, nearest gene; Trait, blood pressure trait analyzed; Ref, reference of the first reports of association in the listed region.

*Indicates that one or more of the previously reported variants in the locus were not on exome array.

**Indicates that the listed variant is the known variant or its proxy ($r^2 > 0.8$ in 1000G EUR).

+Indicates that the listed gene had an unconditional SKAT P -value $< 2 \times 10^{-6}$ (see Supplementary Table 9).

1 Table 3 | Newly identified independent BP-associated rare SNVs (MAF \leq 0.01) at known loci in UK Biobank only

Locus ID	rsID	Chr:Position	Gene	Info	EA/OA	Consequence	Trait	Unconditional SNV analysis			FINEMAP output		Ref	
								EAF	β	P-value	Common SNVs in top configuration	PP of n SNVs		\log_{10} BF
5	rs41300100	1:11908146	<i>NPPA</i>	0.82	G/C	5' UTR	SBP	0.010	-0.10	4.70x10 ⁻²¹	rs2982373, rs50666, rs55892892	0.55	122.50	9,2,79
18	rs756799918	1:153464738	<i>RN7SL44P</i>	0.89	T/C	intergenic	SBP	0.0004	0.26	4.30x10 ⁻⁷	rs12030242	0.36	27.49	14
28	rs1805090	1:230840034	<i>AGT</i>	NA	T/G	missense	SBP	0.0025	0.11	6.80x10 ⁻⁸	rs3889728, rs2493135	0.79	26.23	8
28	rs539645495	1:230860071	<i>RP11-99J16_A.2</i>	0.97	G/A	intron, non-coding transcript	DBP	0.0024	0.13	3.20x10 ⁻⁹	rs2493135, rs3889728	0.83	30.97	8
33	rs56152193	2:20925891	<i>LDAH</i>	0.76	C/G	intron	PP	0.0006	-0.23	8.10x10 ⁻⁷	rs7255	0.36	17.95	17, 16
55	rs759606582	2:178325956	<i>AGPS</i>	0.96	G/A	intron	PP	0.0003	0.29	1.90x10 ⁻⁷	rs56726187	0.57	7.48	16
72	rs555934473	3:48899332	<i>SLC25A20</i>	0.74	T/G	intron	DBP	0.0012	-0.17	2.50x10 ⁻⁶	rs36022378, rs6442105, rs6787229	0.25	35.71	17, 16, 6, 11
73	rs76920163	3:53857055	<i>CHDH</i>	0.96	G/T	intron	SBP	0.0059	0.10	3.80x10 ⁻¹³	rs3821843, rs7340705, rs11707607	0.58	29.45	18, 16
	rs144980716	3:53776904	<i>CACNA1D</i>	0.91	A/G	intron	PP	0.0065	0.07	2.60x10 ⁻⁸	rs36031811, rs77347777	0.57	18.42	
85	rs547947160	3:141607335	<i>ATP1B3</i>	0.75	G/A	intron	PP	0.0008	0.20	6.00x10 ⁻⁶	rs6773662	0.54	7.040	13
86	rs545513277	3:143113550	<i>SLC9A9</i>	0.70	A/G	intron	PP	0.0006	-0.24	6.90x10 ⁻⁶	rs1470121	0.56	11.97	16
92	rs186525102	3:185539249	<i>IGF2BP2</i>	0.85	A/G	intron	SBP	0.0086	-0.06	6.70x10 ⁻⁷	rs4687477	0.56	8.08	17
94	rs111620813	4:8293193	<i>HTRA3</i>	NA	A/G	missense	PP	0.0100	-0.05	2.00x10 ⁻⁶	rs28734123	0.53	12.54	18

132	rs181585444	5:129963509	<i>AC005741.2</i>	0.83	C/T	intergenic	DBP	0.0003	-0.30	3.80x10 ⁻⁶	rs274555	0.55	10.70	14, 13
137	rs546907130	6:8156072	<i>EEF1E1</i>	0.90	T/C	intergenic	SBP	0.0017	-0.14	1.90x10 ⁻⁷	rs3812163	0.70	8.57	16
141	rs72854120	6:39248533	<i>KCNK17</i>	0.91	C/T	intergenic	SBP	0.0073	-0.08	3.10x10 ⁻⁹	rs2561396	0.76	10.49	16
141	rs72854118	6:39248092	<i>KCNK17</i>	0.91	G/A	intergenic	DBP	0.0072	-0.07	2.70x10 ⁻⁷	rs1155349	0.85	11.12	16
164	rs138890991	7:40804309	<i>SUGCT</i>	0.94	C/T	intron	PP	0.0100	0.06	1.60x10 ⁻⁷	rs17171703	0.77	19.08	17
179	rs561912039	7:150682950	<i>NOS3</i>	0.74	T/C	intergenic	DBP	0.0017	-0.13	6.40x10 ⁻⁶	rs3793341, rs3918226, rs6464165, rs7788497, rs891511	0.34	81.75	9,14,10
183	rs570342886	8:23380012	<i>SLC25A37</i>	0.85	C/G	intergenic	DBP	0.0001	-0.48	9.80x10 ⁻⁷	rs7842120	0.58	15.74	16
190	rs201196388	8:95265263	<i>GEM</i>	NA	T/C	splice donor	PP	0.0005	0.26	2.40x10 ⁻⁹	rs2170363	0.34	31.80	16, 78
193	rs532252660	8:120587297	<i>ENPP2</i>	0.79	T/C	intron	DBP	0.0025	-0.11	4.10x10 ⁻⁷	rs7017173	0.81	26.53	6
193	rs181416549	8:120678125	<i>ENPP2</i>	0.84	A/G	intron	PP	0.0026	0.20	5.10x10 ⁻²¹	rs35362581, rs80309268	0.95	113.21	6
212	rs138765972	10:20554597	<i>PLXDC2</i>	0.94	C/T	intron	DBP	0.0075	-0.07	4.40x10 ⁻⁸	rs61841505	0.49	9.06	16
219	rs192036851	10:64085523	<i>RP11-120C12.3</i>	0.92	C/T	intergenic	SBP	0.0062	0.06	6.40x10 ⁻⁶	rs10995311	0.28	19.55	16, 13
234	rs150090666	11:14865399	<i>PDE3B</i>	NA	T/C	stop gained	DBP	0.0010	-0.16	5.20x10 ⁻⁷	rs11023147, rs2597194	0.55	12.93	16
242	rs139620213	11:61444612	<i>DAGLA</i>	0.89	T/C	upstream gene	PP	0.0019	0.11	5.90x10 ⁻⁶	rs2524299	0.48	6.64	15
246	rs540659338	11:89183302	<i>NOX4</i>	0.85	C/T	intron	PP	0.0027	-0.14	2.60x10 ⁻¹⁰	rs2289125, rs494144	0.62	58.09	17, 16
260	rs186600986	12:53769106	<i>SP1</i>	0.91	A/G	upstream gene	PP	0.0030	-0.09	1.10x10 ⁻⁶	rs73099903	0.48	12.91	19
266	rs137937061	12:111001886	<i>PPTC7</i>	0.74	A/G	intron	SBP	0.0048	-0.09	1.30x10 ⁻⁶	rs9739637, rs35160901, rs10849937, rs3184504	0.34	55.74	16, 4, 5
268	rs190870203	12:123997554	<i>RILPL1</i>	0.85	T/G	intron	PP	0.0020	0.12	1.70x10 ⁻⁷	rs4759375	0.72	9.50	13
270	rs541261920	13:30571753	<i>RP11-629E24.2</i>	0.79	G/C	intergenic	SBP	0.0005	0.24	9.20x10 ⁻⁶	rs7338758	0.54	10.09	16
281	rs149250178	14:100143685	<i>HHIPL1</i>	0.75	A/G	3' UTR	DBP	0.0004	-0.29	2.30x10 ⁻⁶	rs7151887	0.51	7.93	16

299	rs139491786	16:2086421	<i>SLC9A3r2</i>	NA	T/C	missense	DBP	0.0068	-0.12	1.60x10 ⁻²⁰	rs28590346, rs34165865, rs62036942, rs8061324	0.57	50.80	16
304	rs2234710	16:30907835	<i>BCL7C</i>	0.79	T/G	upstream gene	SBP	0.0075	-0.08	2.30x10 ⁻⁹	-	0.52	6.29	17, 16
304*	rs148753960	16:31047822	<i>STX4</i>	0.89	T/C	intron	PP	0.0099	-0.07	1.80x10 ⁻⁹	rs7500719	0.42	12.21	17, 16
317	rs756906294	17:42323081	<i>SLC4A1</i>	0.73	T/C	downstream gene	PP	0.0030	0.01	8.30x10 ⁻⁶	rs66838809	0.27	18.94	17
322	rs16946721	17:61106371	<i>TANC2</i>	0.91	G/A	intron	DBP	0.0100	-0.07	1.40x10 ⁻¹¹	rs1867624, rs4291	0.51	20.91	17, 16
333	rs55670943	19:11441374	<i>RAB3D</i>	0.87	C/T	intron	SBP	0.0085	-0.10	2.10x10 ⁻¹⁷	rs12976810, rs4804157, rs160838, rs167479	0.78	85.45	13-15
346*	rs149972827	20:30413439	<i>MYLK2</i>	0.98	A/G	intron	SBP	0.0036	-0.10	6.20x10 ⁻⁹	-	0.85	9.86	16
362	rs115089782	22:42329632	<i>CENPM</i>	0.93	T/C	intergenic	SBP	0.0001	0.53	4.20x10 ⁻⁶	rs139919	0.44	14.12	17, 13

2 FINEMAP²⁵ was used to identify the most likely causal variants within the known loci (defined in Supplementary Table 1) using the BOLT-LMM results in UKBB,
3 the full detailed listing of results is provided in Supplementary Table 8. Locus ID, the known locus identifier provided in Supplementary Table 1; Chr:Position,
4 chromosome and physical position in Build 37; Info, imputation information score, NA indicates that the SNV was genotyped and not imputed; EA/OA, Effect
5 allele and other allele, respectively; AA, amino acid change; Effect, predicted effect of the listed SNV; EAF, effect allele frequency; β , single variant effect
6 estimate for the rare variant in the BOLT-LMM analysis; *P*-value, the single variant *P*-value from the mixed model in the BOLT-LMM analysis; PP of *n* SNVs, the
7 posterior probability of the number of causal variants; Log₁₀BF, log₁₀ Bayes factor for the top configuration; Gene, nearest gene; Trait, blood pressure trait
8 analyzed; Ref, reference of the first reports of association in the listed region.
9 rs540659338 identified in UK Biobank in *NOX4* has $r^2 = 1$ in 1000G EUR with rs56061986 identified in the GCTA analysis in Table 4.
10 *Variants at these loci are in LD with GCTA variants (Table 2): at locus 304, $r^2 = 0.876$ between rs148753960 and rs61738491; at locus 346, $r^2 = 0.952$ between
11 rs149972827 and rs45499294.

12 **Online Methods**

13

14 The statistical methods used and analytical packages used are further detailed in the Life Sciences
15 Reporting Summary.

16

17 **Participants.** The cohorts contributing to Stage 1 of the EAWAS comprised 92 studies from four
18 consortia (CHARGE, CHD Exome+, GoT2D:T2DGenes, ExomeBP), and UK Biobank (UKBB)
19 totalling 870,217 individuals of European (EUR, $n = 810,865$), African Ancestry (AA, $n = 21,077$),
20 South Asian (SAS, $n = 33,689$), and Hispanic (HIS, $n = 4,586$) ancestries. Study-specific
21 characteristics, sample quality control and descriptive statistics for the new studies are provided in
22 Supplementary Tables 23 and 24 (and in Supplementary Table 1 and 2 of Surendran *et al.*¹³
23 (<https://media.nature.com/original/nature-assets/ng/journal/v48/n10/extref/ng.3654-S2.xlsx>) and
24 Supplementary Table 20 of Liu *et al.*¹⁴ ([https://media.nature.com/original/nature-](https://media.nature.com/original/nature-assets/ng/journal/v48/n10/extref/ng.3660-S1.pdf)
25 [assets/ng/journal/v48/n10/extref/ng.3660-S1.pdf](https://media.nature.com/original/nature-assets/ng/journal/v48/n10/extref/ng.3660-S1.pdf)) for the previously published studies).

26 For EAWAS, summary association statistics were requested (for the SNVs with $P < 5 \times 10^{-8}$,
27 outside of known BP loci) from the following cohorts: 127,478 Icelanders from deCODE; 225,113
28 EUR, 63,490 AA, 22,802 HIS, 2,695 NAM (Native Americans), and 4,792 EAS (East Asians) from
29 the Million Veterans Program (MVP); and 1,505 EUR and 792 AA individuals from the Genetic
30 Epidemiology Network of Arteriopathy (GENOA). In total, following the data request, 448,667
31 individuals of EUR ($n = 354,096$), AA ($n = 63,282$), HIS ($n = 22,802$), NAM ($n = 2,695$), and EAS
32 ($n = 4,792$) ancestries were available for meta-analyses with Stage 1. Study specific characteristics
33 are provided in Supplementary Tables 23 and 24.

34 Stage 1 of the RV-GWAS used data from 445,360 EUR individuals from UKBB
35 (Supplementary Tables 23 and 24, Supplementary Information), and rare variants were followed up
36 in a data request involving 225,112 EUR individuals from MVP.

37 All participants provided written informed consent, and the studies were approved by their
38 local research ethics committees and/or institutional review boards. The BioVU biorepository
39 performed DNA extraction on discarded blood collected during routine clinical testing, and linked to
40 de-identified medical records.

41

42 **Phenotypes.** SBP, DBP, PP and HTN were analyzed. Details of the phenotype measures for the
43 previously published studies can be found in the Supplementary Information of the Surendran *et al.*
44 and Liu *et al.* papers ([https://media.nature.com/original/nature-](https://media.nature.com/original/nature-assets/ng/journal/v48/n10/extref/ng.3654-S2.xlsx)
45 [assets/ng/journal/v48/n10/extref/ng.3654-S2.xlsx](https://media.nature.com/original/nature-assets/ng/journal/v48/n10/extref/ng.3654-S2.xlsx); [https://media.nature.com/original/nature-](https://media.nature.com/original/nature-assets/ng/journal/v48/n10/extref/ng.3660-S1.pdf)
46 [assets/ng/journal/v48/n10/extref/ng.3660-S1.pdf](https://media.nature.com/original/nature-assets/ng/journal/v48/n10/extref/ng.3660-S1.pdf)), and further details of the additional studies are
47 provided in Supplementary Table 24 and Supplementary Information. Typically, the average of two
48 baseline measurements of SBP and DBP were used. For individuals known to be taking BP-lowering
49 medication, 15 and 10 mmHg were added to the raw SBP and DBP values, respectively, to obtain
50 medication-adjusted values⁴⁹. PP was defined as SBP minus DBP after medication adjustment. For
51 HTN, individuals were classified as hypertensive cases if they satisfied at least one of the following
52 criteria: (i) SBP \geq 140 mmHg, (ii) DBP \geq 90 mmHg, or (iii) use of antihypertensive or BP-lowering
53 medication. All other individuals were considered controls. Further information on study-specific BP
54 measurements is provided in Supplementary Table 24. Residuals from the null model obtained after
55 regressing the medication-adjusted trait on the covariates (age, age², sex, BMI, principal components
56 (PCs) to adjust for population stratification, in addition to any study-specific covariates) within a
57 linear regression model were ranked and inverse normalized (Supplementary Information).

58

59 **Genotyping.** The majority of the studies were genotyped using one of the Illumina HumanExome
60 BeadChip arrays (Supplementary Table 24). An exome chip quality control standard operating
61 procedure (SOP: <https://ruderd02.u.hpc.mssm.edu/Exome-chip-QC.pdf>) developed by A. Mahajan,

62 N.R.R. and N.W.R. at the Wellcome Trust Centre for Human Genetics, University of Oxford was
63 used by some studies for genotype calling and quality control, while the CHARGE implemented an
64 alternative approach⁵⁰ (Supplementary Table 24 and Supplementary Tables 3 and 21, respectively, of
65 Surendran et al.¹³ and Liu et al.¹⁴). All genotypes were aligned to the plus strand of the human
66 genome reference sequence (build 37) before any analyses and any unresolved mappings were
67 removed. UKBB, MVP, and deCODE were genotyped using GWAS arrays (Supplementary Table
68 24).

69
70 **Exome array meta-analyses.** Study-specific analyses were performed to test for the association of
71 247,315 SNVs with SBP, DBP, PP and HTN in 810,865 individuals of European ancestry (75 EUR
72 studies) and additionally in 59,352 individuals of non-European ancestry comprising of SAS (5
73 studies), AA (10 studies), and HIS (2 studies) individuals (Supplementary Information). Study-
74 specific association summaries were meta-analyzed in Stage 1 using an inverse-variance-weighted
75 fixed-effect meta-analyses implemented in METAL⁵². Fixed effect and random effects meta-analyses
76 showed concordant results (Supplementary Table 2). For the binary trait (HTN), we performed
77 sample-size-weighted meta-analysis.

78 Minimal inflation in the association test statistic, λ , was observed ($\lambda = 1.18$ for SBP, 1.20 for
79 DBP, 1.18 for PP, and 1.18 for HTN in the EUR meta-analyses; and $\lambda = 1.19$ for SBP, 1.20 for DBP,
80 1.18 for PP, and 1.16 for HTN in the PA meta-analyses). The meta-analyses were performed
81 independently at three centres, and results were found to be concordant across the centres.

82 Following Stage 1, SNVs outside of known BP-associated regions with $P < 5 \times 10^{-8}$ were looked up
83 in individuals from the MVP, deCODE, and GENOA studies (data request). Two meta-analyses of
84 the three additional studies for each trait were performed by two independent analysts, one involving
85 EUR individuals (354,096 participants) only and one PA (448,667 participants). Likewise, two Stage
86 2 meta-analyses for each trait were performed by two independent analysts, one EUR (1,167,961

87 participants) and one PA (1,318,884 participants). SNVs with (a conservative) $P < 5 \times 10^{-8}$ in the
88 Stage 2 meta-analysis, with consistent directions of effect in Stage 1 and data request studies and no
89 evidence of heterogeneity ($P > 0.0001$), were considered potentially novel⁵³.

90

91 **RV-GWAS.** Rare SNVs with $P < 5 \times 10^{-8}$ (a widely accepted significance threshold^{54,55}) in the
92 inverse variance-weighted meta-analysis of UKBB and MVP, with consistent directions of effect in
93 Stage 1 and MVP and no evidence of heterogeneity ($P > 0.0001$), were considered potentially novel.

94

95 **Quality control.** As part of the sample QC, plots comparing inverse of the standard error as a
96 function of the square root of study sample size for all studies were manually reviewed for each trait,
97 and phenotype-specific study outliers were excluded. In addition, inflation of test static was
98 manually reviewed for each study and for each phenotype and confirmed minimal or no inflation
99 prior to Stage 1 meta-analyses. For EAWAS and RV-GWAS, we performed our own QC for
100 genotyped variants as we were specifically interested in rare variants and knew that these were most
101 vulnerable to clustering errors. Full details of UKBB QC are provided in the Supplementary Note.
102 To ensure that the variants we reported are not influenced by technical artefacts and not specific to a
103 certain ancestry, we ensured that there was no heterogeneity and also that the variants had consistent
104 direction of effects between Stage 1 and the data request studies (MVP+deCODE+GENOA). In
105 addition, we ensured that the association was not driven by a single study. For variants reported in
106 RV-GWAS and EAWAS, we reviewed the cluster plots for clustering artefacts and removed poorly
107 clustered variants. Lastly, for RV-GWAS, if the variant was available in UKBB whole exome data
108 (~50K individuals), we ensured that the minor allele frequencies were consistent with the imputed
109 MAF despite restricting the reporting of only variant with a good imputation quality (INFO > 0.8).

110

111 **Definition of known loci.** For each known variant, pairwise LD was calculated between the known
112 variant and all variants within the 4-Mb region in the 1000 Genomes phase 3 data restricted to
113 samples of European (EUR) ancestry. Variants with $r^2 > 0.1$ were used to define a window around
114 the known variant. The region start and end were defined as the minimum position and maximum
115 position of variants in LD within the window ($r^2 > 0.1$), respectively. Twelve variants were not in
116 1000 Genomes, and for these variants, a ± 500 -kb window around the known variant was used. The
117 window was extended by a further 50 kb and overlapping regions were merged (Supplementary
118 Table 1).

119
120 **Conditional analyses.** Within the new BP loci, we defined a region based on LD (Supplementary
121 Table 1) within which conditional analysis was performed (five variants were not in the 1000G
122 panel, and for these we established a ± 500 -kb window definition). Conditional and joint association
123 analysis as implemented in Genome-wide Complex Trait Analysis (GCTA v1.91.4)²² was performed
124 using the EAWAS results to identify independent genetic variants associated with BP traits within
125 newly identified and known regions available in the exome array. We restricted this analysis to the
126 summary data from Stage 1 EUR EAWAS meta-analyses ($n = 810,865$) as LD patterns were
127 modelled using individual level genotype data from 57,718 EUR individuals from the CHD Exome+
128 consortium. Variants with $P_{\text{joint}} < 1 \times 10^{-6}$ were considered conditionally independent.

129 We used the UKBB GWAS results and FINEMAP²⁵ v1.1 to fine-map the known BP-
130 associated regions in order to identify rare variants that are associated with BP independently of the
131 known common variants (Supplementary Note; due to lack of statistical power, we did not use
132 UKBB GWAS data alone to perform conditional analyses within the new EAWAS loci). For each
133 known region, we calculated pairwise Pearson correlation for all SNVs within a 5-Mb window of the
134 known SNVs using LDstore v1.1. Z-scores calculated in the UKBB single-variant association
135 analyses were provided as input to FINEMAP along with the correlation matrix for the region. We

136 selected the configuration with the largest Bayes Factor (BF) and largest posterior probability as the
137 most likely causal SNVs. We considered causal SNVs to be significant if the configuration cleared a
138 threshold of $\log_{10}\text{BF} > 5$ and if the variants in the configuration had an unconditional association of
139 $P \leq 1 \times 10^{-6}$. We examined the validity of the SNVs identified for the most likely configuration by
140 checking marginal association P -values and LD (r^2) within UKBB between the selected variants. For
141 loci that included rare variants identified by FINEMAP, we validated the selected configuration
142 using a linear regression model in R.

143

144 **Gene-based tests.** Gene-based tests were performed using the sequence kernel association test
145 (SKAT)²⁶ as implemented in the rareMETALS package version 7.1
146 (<https://genome.sph.umich.edu/wiki/RareMETALS>) (which allows for the variants to have different
147 directions and magnitudes of effect) to test whether rare variants in aggregate within a gene are
148 associated with BP traits. For the EAWAS, two gene-based meta-analyses were performed for
149 inverse-normal transformed DBP, SBP, and PP, one of EUR and a second PA including all studies
150 with single-variant association results and genotype covariance matrices (up to 691,476 and 749,563
151 individuals from 71 and 88 studies were included in the EUR and PA gene-based meta-analyses,
152 respectively).

153 In UKBB, we considered summary association results from 364,510 unrelated individuals
154 only. We annotated all SNVs on the exome array using VEP²⁷. A total of 15,884 (EUR) and 15,997
155 genes (PA) with two or more variants with $\text{MAF} \leq 0.01$ annotated with VEP as high or moderate
156 effects were tested. The significance threshold was set at $P < 2.5 \times 10^{-6}$ (Bonferroni adjusted for
157 ~20,000 genes).

158 A series of conditional gene-based tests were performed for each significant gene. To verify
159 the gene association was due to more than one variant (and not due to a single sub-genome-wide
160 significance threshold variant), gene tests were conditioned on the variant with the smallest P -value

161 in the gene (top variant). Genes with $P_{\text{conditional}} < 1 \times 10^{-4}$ were considered significant, which is in line
162 with locus-specific conditional analyses used in other studies⁵⁶. In order to ensure that gene
163 associations located in known or newly identified BP regions (Supplementary Note and
164 Supplementary Table 1) were not attributable to common BP-associated variants, analyses were
165 conditioned on the conditionally independent known/novel common variants identified using GCTA
166 within the known or novel regions, respectively, for the EAWAS (or identified using FINEMAP for
167 the GWAS). Genes mapping to either known or novel loci with $P_{\text{conditional}} < 1 \times 10^{-5}$, were considered
168 significant. The P -value to identify gene-based association not driven by a single variant was set in
169 advance of performing gene-based tests and was based on an estimation of the potential number of
170 genes that could be associated with BP.

171

172 **Mendelian randomization with CVDs.** We used two-sample MR to test for causal associations
173 between BP traits and any stroke (AS), any ischemic stroke (IS), large artery stroke (LAS),
174 cardioembolic stroke (CE), small vessel stroke (SVS), and coronary artery disease (CAD). All the
175 new and known BP-associated SNVs (including conditionally independent SNVs) listed in
176 Supplementary Tables 2, 3, 5, 7 and 8, were used as instrumental variables (IVs). In addition to trait
177 specific analyses, we performed an analysis of “generic” BP, in which we used the SNVs associated
178 with any of the traits. Where variants were associated with multiple BP traits, we extracted the
179 association statistics for the trait with the smallest P -value (or the largest posterior probability for the
180 known loci). To exclude potentially invalid (pleiotropic) genetic instruments, we used
181 PhenoScanner³⁵ to identify SNVs associated with CVD risk factors, cholesterol
182 (LDL/HDL/triglycerides (TG)), smoking, type 2 diabetes (T2D) and atrial fibrillation (AF)
183 (Supplementary Table 22) and removed these from the list of IVs. We extracted estimates for the
184 associations of the selected instruments with each of the stroke subtypes from the MEGASTROKE

185 PA GWAS results (67,162 cases; 454,450 controls)⁶³ and from a recent GWAS for CAD⁶⁴. We
186 applied a Bonferroni correction ($P < 0.05/6 = 0.0083$) to account for the number of CVD traits.
187 We used the inverse-variance weighting method with a multiplicative random-effects because we
188 had hundreds of IVs for BP⁶⁵. We performed MR-Egger regression, which generates valid estimates
189 even if not all the genetic instruments are valid, as long as the Instrument Strength Independent of
190 Direct Effect assumption holds⁶⁶. We note that MR-Egger has been shown to be conservative⁶⁶, but
191 has the useful property that the MR-Egger-intercept can give an indication of (unbalanced)
192 pleiotropy, which allowed us to test for pleiotropy amongst the IVs. We used MR-PRESSO to detect
193 outlier IVs⁶⁷. To assess instrument strength, we computed the F-statistic⁶⁸ for the association of
194 genetic variants with SBP, DBP and PP, respectively (Supplementary Information and
195 Supplementary Table 22). We also assessed heterogeneity using the Q-statistic. Although these
196 methods may have different statistical power, the rationale is that, if these methods give a similar
197 conclusion regarding the association of BP and CVD, then we are more confident in inferring that
198 the positive results are unlikely to be driven by violation of the MR assumptions⁶⁹.

199 Moreover, we used multivariable MR (mvMR) to estimate the effect of multiple variables on
200 the outcome^{65,70}. This is useful when two or more correlated risk factors are of interest, e.g. SBP and
201 DBP, and may help to understand whether both risk factors exert a causal effect on the outcome, or
202 whether one exerts a leading effect on the outcome. Thus, we used multiple genetic variants
203 associated with SBP and DBP to simultaneously estimate the causal effect of SBP and DBP on
204 CVDs.

205 All analyses were performed using R version 3.4.2 with R packages ‘TwoSampleMR’ and
206 ‘MendelianRandomization’ and ‘MRPRESSO’.

207

208 **Metabolite quantitative trait loci and Mendelian randomization analyses.** Plasma metabolites
209 were measured in up to 8,455 EUR individuals from the INTERVAL study^{71,72} and up to 5,841 EUR

210 individuals from EPIC-Norfolk⁷³ using the Metabolon HD4 platform. In both studies, 913
211 metabolites passed QC and were analyzed for association with ~17 million rare and common
212 genetic variants. Genetic variants were genotyped using the Affymetrix Axiom UK Biobank array
213 and imputed using the UK10K+1000Genomes or the HRC reference panel. Variants with INFO >
214 0.3 and MAC > 10 were analyzed. Phenotypes were log-transformed within each study, and
215 standardized residuals from a linear model adjusted for study-specific covariates were calculated
216 prior to the genetic analysis. Study-level genetic analysis was performed using linear mixed models
217 implemented in BOLT-LMM to account for relatedness within each study, and the study-
218 level association summaries were meta-analyzed using METAL prior to the lookup of novel BP
219 variants for association with metabolite levels.

220 The same methodology for MR analyses as implemented for CVDs was also adopted to test
221 the effects of metabolites on BP. Causal analyses were restricted to the list of 14 metabolites that
222 overlapped our BP-associations and were known. We used a Bonferroni significance threshold ($P <$
223 $0.05/14 = 0.0036$), adjusting for the number of metabolites being tested. We also tested for a reverse
224 causal effect of BP on metabolite levels. The IVs for the BP traits were the same as those used for
225 MR with CVDs. For the mvMR analysis of metabolites with BP, we included 3-
226 methylglutaryl carnitine(2) and the three metabolites that shared at least one IV with 3-
227 methylglutaryl carnitine(2) in the mvMR model. A union set of genetic IVs for all the metabolites
228 were used in the mvMR model to simultaneously estimate the effect size of each metabolite on DBP.

229

230 **Colocalization of BP associations with eQTLs.** Details of kidney-specific eQTL are provided in
231 Supplementary Information. Using the phenoscanner lookups to prioritize BP regions with eQTLs in
232 GTEx version 7, we performed joint colocalization analysis with the HyPrColoc package in R³¹
233 (<https://github.com/jrs95/hyprcoloc>; regional colocalization plots,
234 <https://github.com/jrs95/gassocplot>). HyPrColoc approximates the COLOC method developed by

235 Giambartolomei et al.⁶² and extends it to allow colocalization analyses to be performed jointly across
236 many traits simultaneously and pinpoint candidate shared SNV(s). Analyses were restricted to SNVs
237 present in all the datasets used (for GTEx data this was 1 Mb upstream and downstream of the center
238 of the gene probe), data were aligned to the same human genome build 37 and strand, and a similar
239 prior structure as the colocalization analysis with cardiometabolic traits was used ($P = 0.0001$ and
240 $\gamma = 0.99$).

241

242 **Gene set enrichment analyses.** In total, 4,993 GO biological process, 952 GO molecular function,
243 678 GO cellular component, 53 GTEx, 301 KEGG, 9537 MGI, and 2645 Orphanet gene sets were
244 used for enrichment analyses (Supplementary Information).

245 We restricted these analyses to the rare BP-associated SNVs (Supplementary Table 4). For
246 each set of gene sets, the significance of the enrichment of the genetically identified BP genes was
247 assessed as the Fisher's exact test for the over-abundance of BP genes in the designated gene set
248 based on a background of all human protein coding genes or, in the case of the MGI gene sets, a
249 background of all human protein-coding genes with an available knock-out phenotype in the MGI
250 database.

251 Results were deemed significant if after multiple testing correction for the number of gene
252 sets in the specific set of gene sets the adjusted P -value < 0.05 . Results were deemed suggestive if
253 the adjusted P -value was between 0.05 and 0.1.

254

255 **Functional enrichment using BP-associated variants.** To assess enrichment of GWAS variants
256 associated with the BP traits in regulatory and functional regions in a wide range of cell and tissue
257 types, we used GWAS Analysis of Regulatory or Functional Information Enrichment with LD
258 Correction (GARFIELD). The GARFIELD method has been described extensively elsewhere^{76,77}. In
259 brief, GARFIELD takes a non-parametric approach that requires GWAS summary statistics as input.

260 It performs the following steps: (i) LD-pruning of input variants; (ii) calculation of the fold
261 enrichment of various regulatory/functional elements; and (iii) testing these for statistical
262 significance by permutation testing at various GWAS significance levels, accounting for MAF, the
263 distance to the nearest transcription start site, and the number of LD proxies of the GWAS variants.
264 We used the SNVs from the full UKBB GWAS of BP traits as input to GARFIELD (Supplementary
265 Table 4).

266

267 **Data availability**

268 Summary association results for all the traits are available for download from:

269 <https://app.box.com/s/1ev9iakptips70k8t4cm8j347if0ef2u>

270 and from the CHARGE dbGaP Summary site, (<https://www.ncbi.nlm.nih.gov/gap/>) accession

271 number phs000930.

272

273

274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322

METHODS-ONLY REFERENCES

49. Tobin, M.D., Sheehan, N.A., Scurrah, K.J. & Burton, P.R. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. *Stat. Med.* **24**, 2911-2935 (2005).

50. Grove, M.L. et al. Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. *PLoS One* **8**, e68095 (2013).

51. Liu, D.J. et al. Meta-analysis of gene-level tests for rare variant association. *Nat. Genet.* **46**, 200-204 (2014).

52. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191 (2010).

53. Fadista, J., Manning, A.K., Florez, J.C. & Groop, L. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. *Eur. J. Hum. Genet.* **24**, 1202-1205 (2016).

54. Flannick, J. et al. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. *Nature* **570**, 71-76 (2019).

55. Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat. Genet.* **50**, 1505-1513 (2018).

56. Mahajan, A. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. *Nat. Genet.* **50**, 559-571 (2018).

57. Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum. Mol. Genet.* **27**, 3641-3649 (2018).

58. Willer, C.J. et al. Discovery and refinement of loci associated with lipid levels. *Nat. Genet.* **45**, 1274-1283 (2013).

59. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105-116 (2010).

60. Scott, R.A. et al. An expanded genome-wide association study of type 2 diabetes in Europeans. *Diabetes* **66**, 2888-2902 (2017).

61. Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat. Genet.* **47**, 1121-1130 (2015).

62. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).

63. Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat. Genet.* **50**, 524-537 (2018).

64. van der Harst, P. & Verweij, N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circ. Res.* **122**, 433-443 (2018).

65. Burgess, S. et al. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. *Eur. J. Epidemiol.* **30**, 543-552 (2015).

66. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* **44**, 512-525 (2015).

67. Verbanck, M., Chen, C.Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.* **50**, 693-698 (2018).

68. Pierce, B.L., Ahsan, H. & Vanderweele, T.J. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. *Int. J. Epidemiol.* **40**, 740-752 (2011).

69. Lawlor, D.A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. *Int. J. Epidemiol.* **45**, 1866-1886 (2016).

70. Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int. J. Epidemiol.* **48**, 713-727 (2019).

71. Di Angelantonio, E. et al. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. *Lancet* **390**, 2360-2371 (2017).

323 72. Astle, W.J. et al. The allelic landscape of human blood cell trait variation and links to common complex
324 disease. *Cell* **167**, 1415-1429 e19 (2016).

325 73. Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective
326 Investigation of Cancer. *Br. J. Cancer* **80 Suppl 1**, 95-103 (1999).

327 74. Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis
328 project. *Nat. Genet.* **45**, 1113-1120 (2013).

329 75. Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification.
330 *Nat. Biotechnol.* **34**, 525-527 (2016).

331 76. Iotchkova, V. et al. Discovery and refinement of genetic loci associated with cardiometabolic risk using
332 dense imputation maps. *Nat. Genet.* **48**, 1303-1312 (2016).

333 77. Iotchkova, V. et al. GARFIELD classifies disease-relevant genomic features through integration of
334 functional annotations with association signals. *Nat. Genet.* **51**, 343-353 (2019).

335 78. Zhu, X. et al. Meta-analysis of correlated traits via summary statistics from GWASs with an application
336 in hypertension. *Am. J. Hum. Genet.* **96**, 21-36 (2015).

337 79. Newton-Cheh, C. et al. Association of common variants in NPPA and NPPB with circulating natriuretic
338 peptides and blood pressure. *Nat. Genet.* **41**, 348-53 (2009).

339

340

341

342

343